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ABSTRACT 
To relieve pain in newborn infants particularly preterm infants is essential in modern neonatology. 
However, there are a number of innate difficulties related to pain assessment and pharmacological 
treatment, which includes in this thesis work. It emanated from our participation in an international 
team that designed and conducted the NEOPAIN multicenter trials, testing the effects of morphine 
analgesia in 898 preterm mechanically ventilated neonates. Primary neurological outcomes were 
defined as death, severe IVH and PVL that were not affected, respectively. However, intermittent 
doses with morphine increased the incidence of composite outcome 24% vs. 15 %. The pre-
emptive morphine infusion did not improve short-term pulmonary outcomes; it extended the 
mechanical ventilation time with one day. Additional morphine doses aggravated the respiratory 
outcomes in preterm neonates with RDS and severity of illness. Because these neonates were 
“sicker” and had greater physiological instability, they required more frequent procedures and pain 
assessments by caregivers, consequently an increased use of additional doses of morphine analgesia. 
However, the pre-emptive morphine infusions reduced pain responsiveness, measured by changes 
in heart rate (HR) p<0.005, blood pressure p<0.001, and decreased PIPP scores (p<0.02), as 
compared with placebo. 
 
The ability of professional NICU staffs to correctly estimate analgesia treatment is limited. Neither 
education (63% to 54%, p=0.60) nor experiences (65% to 55%, p=0.28) in the NICU affected their 
ability to assess whether the neonates had received analgesia or not, highlighting the difficulties in 
assessment of prolonged neonatal pain. 
 
Term newborn infants delivered vaginally (VD) reacted with less responsiveness (facial expression 
36.6%, cry 21.6%, and HR 4.2 %, p=0.04-0.001) after injection of vitamin K as compared to the 
infants delivered by caesarean section (CS). VD infants showed increased physiological reactivity to 
graded painful stimuli in the first hours following birth (p<0.001 and p=0.04, for high- and low- 
intensity stimuli, respectively) but no such increase occurred in the CS newborn infants (p=0.96 and 
p=0.52). These findings suggest that vaginal delivery leads to a foetal inhibition of pain and thermal 
sensory processing soon after birth. 
 
Both painful and tactile stimuli resulted in hemodynamic responses in the parietal (somatosensory) 
cortex, monitored by NIRS in preterm neonates, but did not occur in the occipital (visual) cortex. 
This sensory perception was accentuated responses in preterm neonates with male sex (p<0.05), 
lower gestational ages (p<0.05), or greater postnatal ages (p<0.001). These nuanced responses of 
preterm infants at the cortical level indicate conscious perception of pain. 
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1 LIST OF ABBREVIATIONS 
 
paCO2 Partial pressure of arterial carbon dioxide (kPa)
ACC 
AGA 
Apgar score 
 
 
APIB 
BIIP 
bpm 
BW 
CBF 
CHEOPS 
CNS 
CRIB 
CRIES 
 
CS 
DPF 
DRG 
DSVNI 
ECG 
EMEA 
GA 
HbH 
HbO2 
Hbtot 
HR 
HRV 
M3G 
M6G 
N2O 
NEC 
NEOPAIN 
NFCS 
NGF 
NICU 
NIPS 
NIRS 
NMI 
OSBD 
PAT 
PCA 
Anterior Cingulate Cortex 
Appropriate weight for Gestation Age 
After Virgina Apgar also explained by Appearance (skin colour), 
Pulse (heart rate), Grimace (reflex, irritability), Activity (muscle 
tone), and Respiration 
Assessment of Preterm Infant´s Behaviour 
Behavioral Indicators of Infant Pain 
Beats per minute (heart) 
Birth weight 
Cerebral blood flow 
Children's Hospital of Eastern Ontario Pain Scale 
Central Nervous System 
Clinical risk index for babies 
Crying, Requires Oxygen, Increased VS, Expression, Sleepless 
(pain scale) 
Caesarean section 
Differential path-length factor 
Dorsal root ganglion 
Distress Scale for Ventilated Newborn Infants 
Electro cardiogram  
European Medicines Agency 
Gestational age, weeks 
Deoxy-haemoglobin 
Oxy-haemoglobin 
Total haemoglobin 
Heart rate 
Heart Rate Variability 
Morphine 3-Glucuronide 
Morphine 6-Glucuronide 
Nitrous oxide 
Necrotizing entercolitis 
Neurologic Outcomes and Pre-emptive Analgesia in Neonates 
Neonatal Facial Coding System (pain scale) 
Nerve growth factor 
Neonatal Intensive Care Unit 
Neonatal Infant Pain Scale 
Near infrared spectroscopy 
Neonatal medical index 
Observational Scale for Behavioural Distress 
Pain Assessment Tool 
Postconceptional age, weeks
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PD 
PNA 
PICU 
PIPP 
PK 
PRBS 
PUMA 
ROP 
SaO2 
SUN 
UGT-2B7 
VAS 
VD 
VLBW 
VS 
Pharmacodynamic 
Post Natal Age, weeks 
Paediatric Intensive Care Unit 
Preterm Infant Pain Profile 
Pharmacokinetic 
Procedural Behavioural Rating Scale 
Paediatric Use marketing Authorisations 
Retinopathy of Prematurity 
Arterial oxygen saturation 
Scale for Use in Newborns (pain scale) 
Uridine 5’-diphosphate Glucuronosyl Transferase-2B7 
Visual analogue scale 
Vaginal delivery 
Very Low Birth Weight 
Vital Signs, including heart rate, blood pressure 
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2 INTRODUCTION 
The capability of the newborn infant to feel and remember pain has been underestimated for a very 
long time, leading to unnecessary pain experiences in this population. Infants and neonates are even 
more sensitive to pain due to immaturity of endogenous modulation. Furthermore the newborn 
infants’ limited ability to communicate their pain; they should have the same human right to be 
alleviated from pain.  
 
The infants brain particularly the preterm brain undergoes an enormous development with regard to 
the branching of neurons, synpatogenesis, wiring and myelination, see Levene et al. 2001, 
Lagercrantz et al. 2002. This development is not only genetically programmed but also influenced by 
input from the sensory organs and spontaneous activity (Fransson et al. 2007). Pain and particularly 
chronic pain may mainly affect the making of the brain and cause permanent injuries (Anand et al. 
1999b; Anand 2000a; Fitzgerald 2005; Anand et al. 2007). 
 
The importance of understanding the development of pain mechanisms is further corroborated by 
the increased survival of extremely preterm infants, who may sustain multiple painful and distressing 
procedures during early life. In Sweden more than 50 % of infants born during the 23rd- 24th 
gestational week survive nowadays (Finnström 1998; Serenius 2004). 
 
The overall objectives of this thesis were to estimate pain by objective methods in preterm and 
newborn infants. More specifically: 
- To assess the short-term neurological and pulmonary effects of pre-emptive analgesia with 
morphine to preterm infants. 
- To record cortical activity in infants sustaining painful procedures. 
- To assess the sensitivity to pain stimuli (vitamin K injection) in infants delivered vaginally 
versus those born after caesarean section. 
- To examine the ability of the neonatal staff to estimate the effect of analgesia treatment. 
Figure 1. Brain development, by courtesy of Hugo Lagercrantz. 
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3 BACKGROUND 
3.1 DEFINITION OF PAIN 
The International Association of the Study of Pain (IASP) defines that pain is “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage or described in 
terms of damage”. According to the IASP “pain is always subjective. Each individual learns the 
application of the word through experiences related to injury in early life” (International Association 
for the Study of Pain 1979; Merskey 1991). 
 
However, this definition of pain by the IASP does not apply humans incapable of self-reporting 
newborn and older infants. Consequently, the “relationships between feeling pain and reporting pain are 
highly context-dependent. They reflect who is eliciting the self-report, the methods used to assess 
pain” (Anand and Craig 1996). The new perspective of the pain definition, as suggested by Anand 
and Craig, has been of immense importance for the development of structured pain assessment 
tools to evaluate individual pain in infants with reduced capabilities to communicate their 
experience. Furthermore, the IASP statement that pain is learned through experiences in early life 
requires additional definitions within the newborn population. Anand and Craig suggest that the 
ability to experience pain is innate and appears early in ontogeny with individual development to 
serve as a signalling system in case of tissue damage. Their theory is based on empirical evidence 
that purports that both behavioural and physiological responses are valid pain indicators. 
Consequently, Anand and Craig propose “behavioural alterations caused by pain are the infantile 
forms of self report and are not, surrogate measures, of pain”. They also stated that “infants, 
children and the cognitively impaired do not have to know, or be able to express the meaning of an 
experience to have the experience of pain” (Anand and Craig 1996). The newborn infant and even 
foetuses respond with programmed withdrawal reflex, grimaces and crying as will be discussed in 
this thesis. 
 
In the early 2000s, AD Craig described pain as a homeostatic emotion, like itch, visceral distension, 
muscle ache, hunger, thirst, “air hunger” and sensual touch. According to AD Craig, pain can either 
be unpleasant (commonly), or pleasant (as when it relieves an intense itch) or a mixture of such 
sensations. The human feeling of pain is both a distinct sensation and a motivation, a specific 
emotion that reflects the behavioural drive located in different areas of the anterior insular cortex 
and anterior cingulate cortex (ACC) (Craig 2003). Emotional responses to pain may be 
quantitatively or qualitatively different in young children as compared to older subjects. 
 
The United Nations Convention on the Rights of the Child recognizes that children belong to a 
vulnerable population and that they are entitled to special consideration in all respects, including 
healthcare. Despite this recognition, inadequate prevention and relief of children’s pain is still 
widespread. This failure reflects shortcomings in recognizing children’s ability to perceive, respond 
to, and be harmed by pain; exaggerated fear of the side effects of analgesics and anaesthetics in 
children; and lack of resources to provide training for clinicians and treatments for children (Levene 
and Quinn 1992; Harrop 2007). 
 
The ability of the newborn infant to feel and remember pain has been underestimated and under 
treated for a very long time, leading to unnecessary pain and discomfort experiences in thousands of 
neonates. Due to the newborn infants limited ability to communicate pain, several myths and 
misconceptions regarding neonatal pain sensitivity have been prevalent (Finnström and Schollin 
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1998). Consequently, it has been generally accepted that infants tolerate pain and discomfort better 
than adults, and that infants do not experience pain as adults since their nervous system is immature. 
The overall awareness that newborns do feel pain and that pain can elicit long-term adverse effects 
is now increasing. Still, many newborn infants undergo repeated painful procedures without 
adequate analgesia (Carbajal et al. 2008; Finnström et al. 1998). There is also a myth that newborns 
do not have a memory of pain, which has contributed to undertreatment pain and negative long 
lasting effects from early painful stimuli. The clinical and experimental pain research over the last 20 
years has discredited these myths and incorrect opinions, but they still do exist (Levene 2005). 
Repetitive mechanical stimulation shows in animal studies with a risk to develop hypersensitivity 
(Eriksson et al. 2005). 
 
There are strong indications that chronic pain may affect the wiring of the neuronal networks 
possibly leading to attention deficit disorders. Whit diffusion tensor imaging showed that white 
matter microstructure of ex-preterm infants lesions in the brain persist at long term follow up at 11 
year. The preterm infant had a lower fractional anisotropy values in the posterior corpus callosum 
and bilaterally in the internal capsules (Nagy et al. 2003). In the newborn infants, functional 
magnetic imaging (fMRI) was used to study the resting-state networks driven by spontaneous signal 
fluctuations (Fransson et al. 2007). How does early pain affect these spontaneous activities with 
cerebral pain processing following NICU care?  
 
Thus it is obvious as stated by IASP, 2007 “The inability to communicate verbally does not negate 
the possibility that an individual is experiencing pain and is in need of appropriate pain-relieving 
treatment.” – Certainly a welcome change for clinicians and researchers dealing with infant pain! 
(IASP ; Johnston et al. 1996) 2007. 
 
The neonatal pain problem is significant, not least in the preterm population. In Sweden the annual 
birth rates is around 100,000 infants per year, see table 1 for definitions of pregnancy duration. 
Almost 1000 infants (1%) are born very preterm in Sweden (Lindam 2008). These infants usually 
need hospital care for 2-4 months, and are at high risk for being exposed to repeated painful 
procedures as part of the medical care. Particularly infants with birth weight below 1000 grams 
survive more often now (Finnström et al. 1998; Serenius et al. 2004; Högberg et al. 2006). 
 
Table 1. Data from the Swedish Medical Birth Register 2006. 
 
DEFINITION GESTATIONAL AGE 
(WEEKS)
NUMBER OF 
BIRTHS (N)
ALL BIRTH 
(%) 
Full term ≥ 37+0 97 965 93.9% 
Preterm 32+0 – 36+6 5 433 5.2 % 
Very preterm 28+0 – 31+6 662 0.6 % 
Extremely preterm < 28 (live born) 308 0.3 % 
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3.2 HISTORICAL PERSPECTIVE ON NEONATAL PAIN 
Opium, produced from the immature seed pods of opium poppies (Papaver somniferum) has been 
used for pain relief for thousands of years. The Egyptian Ebers Papyrus, ca 1500 BC., describes a 
way to “prevent the excessive crying of children” using grains of the poppy-plant strained to a pulp. 
In these early times, humans believed pain was related to evil and magic, hence the responsibility of 
providing relief was left to sorcerers and priests. Also the Greece Hippocrates, (460 BC-370 BC), 
noted that the gingiva surfaces in teething infants was highly sensitive to pain and concluded at this 
time, that pain was tolerated less in infants than adults (Chadwick 1951). Cornelius Celsus (1st 
century A.D.), described the use of opium and alcohol as a common anaesthetics drugs during 
surgical operations and pain relief in young children, at that time, mainly to avoid stomach problems 
(Spencer 1994). The Greek physician Galen (130-200 A.D.), was experienced in trauma surgery and 
advised the use of alcohol to relieve pain. He described the crying in the newborn infant as 
associated with pain and discomfort (Still 1931). Nils Rosén von Rosenstein (1706-1773) is 
considered to be the father of modern paediatrics. In his book “The diseases of children, and their 
remedies” (1764, translated to English in 1776) he described various drugs to alleviate pain in 
children. 
 
René Descartes, the French mathematician, scientist and philosopher who died in Stockholm 1650, 
presented some of the earliest theories of pain perception. He described acute physiological pain, 
such as burning injury, as a bell ringing in the brain, a view that has been completely discarded by 
modern science (Harrop 2007), see the cover to this thesis. 
 
Morphine was first synthesized from opium in 1806 by Sertürner (Brownstein 1993), a German 
pharmacist, who named the drug morphium after Morpheus, the Greek god of dreams. Morphine 
came into more general use half a century later (Brownstein 1993). In 1848, Henry Bigelow at the 
American Medical Association stated that pain treatment was completely unnecessary in newborn 
infants, since infants did not remember their suffering. Pain was thus associated with memory, 
intelligence and rationality, following the discovery of anaesthesia. At this time the status of 
newborn infants was placed at the level of primates (Pernick 1985). 
 
In 1872, Darwin described in his book “The Expression of the Emotions in Man and Animals”, 
that the emotions necessary for survival, they appear early, and pain is the first part of the sensory 
system that is affected by evolution. For example, the signalling of hunger and tissue damage is 
obviously the most necessary emotions for survival of the newly born, and therefore will appear 
earlier than any other adapted behaviours during development (Darwin 1872). 
 
Until recently, it was questioned whether newborns can perceive pain and whether specific pain 
receptors and pathways were sufficiently developed at birth to result in a response to pain. The 
“Liverpool technique” was introduced in the end of the1950s, for newborn infants, which used high 
doses of muscular relaxants with low doses of nitrous oxide (N2O), i.e. none or very low-dose of 
analgesia was given to the surgical paediatric patients. In Smith’s “Textbook of Anaesthesia” from 
1963 the cerebral cortex of infants was regarded as underdeveloped. Cortical activity was equivalent 
to a deeply anesthetized patient lacking brain activities, and consequently the newborns were 
incapable of feeling pain. 
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The medical literature before the 1970s is essentially lacking any formal reviews or research 
regarding the management of pain in children. A report from 1968 describes that only two out of 60 
postoperative patients received any analgesia (Swafford 1968). 
 
During the late 1980´s, a series of studies demonstrated that preterm infants undergoing surgery 
with minimal anaesthesia, which was at that time a standard practice, exhibited significant negative 
responses to surgery which affected both morbidity and mortality (Anand and Hickey 1987; Anand 
et al. 1987; Anand and Aynsley-Green 1988; Anand et al. 1990). These studies were “eye openers”, 
leading to a public debate initiated by parents’, which culminated in a series of editorials in medical 
journals during the late 1980s. The impact of this research was almost immediately evident and a 
significant progress in postoperative pain treatment from 1974 to 1991, was demonstrated, with an 
increase from 24 to 968 administered doses of analgesia in one institution (Asprey 1994). 
 
At the same time Fitzgerald et al. described pain transmission in the neonate and also identified 
serious negative consequences from undertreatment of neonatal pain. These studies had a dramatic 
impact on the neonatal intensive care units (NICU), with changed practices towards increasing pain 
treatment (Fitzgerald et al. 1989; Reynolds and Fitzgerald 1995). 
 
3.3 PHYSIOLOGY OF PAIN 
The nature and purpose of pain is to act as a protective mechanism for the body. The pain system 
consists of receptors that transmit pain sensation to peripheral nerves which end in the central 
nervous system. The developing nervous system in the newborn infants is characterized by 
functional and structural plasticity, which is especially sensitive to the centre of sensory and pain 
processing (Narsinghani and Anand 2000; Evans et al. 2001; Levene 2001; Lagercrantz 2002). 
 
Pain itself stimulates a catabolic state that will increase tissue injury, delay and prevent healing, and 
may also lead to increased morbidity and mortality in critically ill newborns. 
 
Infants have lower pain thresholds, their responses are less synchronized, and they have longer 
lasting spinal reflex muscle contractions as response to mechanical skin stimulation than adults 
(Fitzgerald et al. 1988; Andrews and Fitzgerald 1994). The cutaneous reflex responses may result in 
pain responses involving movements from the whole body (e.g. wriggling, rolling), and simultaneous 
responses from other extremities, although as the infants mature the responses become more 
restricted to defined parts of the body. 
 
The ill or very preterm newborn may become exposed a large numbers of painful and distressing 
procedures as part of medical diagnostic and therapeutic interventions. Typical interventions are 
venipuncture, heel lancing, lumbar puncture and vaccination. Such skin breaking procedures trigger 
immediate pain responses, as a strong warning of bodily injury, which may also be observed by 
caregivers. It is important to remember that the pain response always occurs but that it may not at 
all times be recognized by the observer (Barker and Rutter 1995a; Carbajal et al. 2008). 
 
 
Experimental data suggest a window of increased sensitivity for permanent changes in the immature 
nervous system as response to nociceptive stimuli in the newborn period (Anand et al. 1999c). 
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Improved knowledge on development of neurobiological pathways and mechanisms associated with 
pain will increase our possibilities to understand and develop methods for assessing and measuring 
pain in the newborn, as well as extend our methods for adequate pain control in this population. 
 
Pain is a multi-layered phenomenon, across all age groups and all animal species that have been 
studied so far.  There are different types of pain:  
• Physiological pain resulting from tissue injury,  
• Inflammatory pain caused by inflammation, cytokine release, or changes in tissue pH, 
• Neuropathic pain secondary to nerve damage or neuroinflammation, or  
• Visceral pain originating from hollow and solid viscera.  
 
Each of these types of pain appears to have unique receptors and mechanisms, although as knock-
out mice experiments show, there is considerable overlap and redundancy within the pain 
processing system.  Nevertheless, some types of pain have specialized nociceptors, nerve fibres, 
neuronal and glial processing in spinal and supraspinal areas.  Some to these mechanisms are 
responsible for phenomena like primary and secondary hyperalgesia, allodynia, temporal or spatial 
summation, sympathetically maintained pain, referred pain, or pain of central origin (Levene 2002).  
 
Peripheral Pain Mechanisms 
Peripheral sensory input to the nervous system is provided by receptors that react to exogenous 
sensory stimuli such as touch, pain, cold, heat, light, sound, smell and olfaction. These receptors are 
highly sensitive to one type of stimulus. 
 
 
Figure 2. Connections between the dorsal horn of the spinal cord, dorsal root ganglia (DRG) and 
target tissue, showing expression of neurotransmitters and receptors, from Narsinghani, Anand, et al. 
Lab Animal 2000. 
 
Nociceptors 
The nociceptors adapt poorly to painful stimuli, instead the fibres become progressively thicker and 
more sensitive as the stimuli continues. This increased pain sensitivity resulting from activation of 
nociceptors is called, hyperalgesia. 
Very little is known about the developmental regulation of nociceptors. Sensory nerve fibres in 
nociceptors and low-threshold mechanoreceptor endings grow out from the dorsal root ganglion 
prenatally and innervate the skin, by birth in the rat and during the 2nd trimester in the human they 
have reached the distal skin of the foot (Payne et al. 1991; Reynolds et al. 1991). The larger A-fibres 
 
 
 
13 
 
develops first, the nerve fibres reach the skin and form the initial cutaneous nerve plexus before the 
C-fibres (Jackman and Fitzgerald 2000). 
 
Nerve growth factor (NGF) is produced in the skin and plays an important role in the normal 
receptor development. NGF also plays a major role later in life, since peripheral release of NGF 
following injury lead to enhanced pain sensation, but also to changes in receptor functions and 
hyperinnervation resulting in pain or hypersensitivity at the site of injury long time after the original 
wound has healed (Arthur 1991). 
 
Inflammation 
An inflammatory response following tissue damage, may persist for hours and days, is associated 
with increased pain sensitivity (hyperalgesia) around the injured area, see figure 3. Ruda et al have 
developed an animal model based on persistent hind paw peripheral inflammation (lasting 5-7 days 
with symptom). The study included behavioural and physiological assessment in addition to 
evaluation of structural changes in the spinal cord. The study demonstrated that inflammatory pain 
during the neonatal period permanently alters pain processing in the spinal cord (Ruda et al. 2000). 
Inflammation increase the sensation in the skin around the injury, and touch will then cause pain in 
this area, expressed as Allodynia. 
 
 
 
Figure 3. Inflammation in the skin activates nociceptors, from the website 
http://www.georgiapainphysicians.com/downloads/m2_slides/2.Pain%20inflammatory%20mediators.jpg 
 
Afferent nerve fibres 
Painful stimuli are transmitted to the central nervous system through two types of fibres. Myelinated 
Aδ-fibres are fast (velocity about 5-25 m/sec), with a diameter 1-3 µm and, while the unmyelinated 
C-fibres are slow (0.1-2 m/sec), very thin with a diameter 0.1-2 µm (Arthur 1991), see figure 4. 
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AXON TYPE  Aα AΒ Aδ C 
Diameter (µm)  13-20 6-12 1-3 0.1-2
Speed (m/s)  80-120 35-75 5-25 0.1-2.0
Function Muscle (spindle 
and golgi tendon) 
Muscle (spindle, 
hair, vibration, 
touch)
Deep pressure, 
pain, cold 
Touch, pressure, 
tickle, aching pain, 
cold, warm
 
 
Figure 4. Primary afferent axons, modified from http://faculty.washington.edu/chudler/axon.gif 
 
 
Figure 5. The different conduction velocities of pain fibres result in a “double” pain response. First 
the fast, sharp and focused pain transmitted through the Aδ-fibres, than the diffuse burning pain 
resulting from activation of the slower C-fibres (acute and chronic pain). Modified from Per Hansson 
et al, Kabi Pharma now Pfizer in the book “Smärta fysiologiska aspekter”  
Pain 
Intensity 
Time 
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Figure 6. Physiological classifications and functions of nerve fibres, from Guyton figure 46-6 Textbook of 
Medical Physiology 1991. 
 
The high-threshold Aδ-fibres are mechanoreceptors responding to pain, while the low-threshold Aβ 
mechanoreceptors respond to touch. Both pathways play important roles to initiate an immediate 
reaction to move away from a noxious stimulus. The low-threshold Aβ mechano-receptors are most 
immature at birth. The number of sensory afferents responding to a needle prick, with pattern and 
amplitude of a response, depends on level of neurotrophic factors in the skin (Snider 1994). 
 
Tissue damage in early postnatal period causes a profound and lasting sprouting response at local A- 
and C-fibres sensory nerve terminals. This results in temporary hyperinnervation that recovers after 
a few weeks in neonates (Reynolds and Fitzgerald 1995). Description of peripheral mechanisms 
related to the development of chronic injury-induced pain (Fried et al. 2001).  
 
Neurotransmitters 
Inflammation produces substances that directly activate or sensitize nociceptors. This activation 
results in decreased pain thresholds, which in turn activates nociceptors and increases their impulse 
activity. Neurotransmitters and signalling molecules are involved in pain pathways that are expressed 
early in the developing nervous system, during sensitive periods corresponding to the time frames 
when the preterm neonates experience NICU treatment. That gives the possibility for the newborn 
infants to respond to pain, with a lack of inhibition and expression result in increased sensitivity 
with risks for injuries (Lagercrantz 2002). 
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Central Pain Mechanisms 
Spinal cord level 
The afferent pain signals to the brain utilise two pathways in the lateral spinothalamic tract a) the 
neospinothalamic tract and b) the paleospinothalamic tract. 
 
 
Figure 7. Supraspinal pain pathway and structures involved in pain processing and their spinal 
connection from Narsinghani, Anand, et al., Lab Animal 2000. 
 
The “fast” type Aδ-fibres transmits mechanical and thermal pain from the periphery to lamina I 
(lamina marginalis) of the dorsal horn. Here the Aδ-fibres synapse with the dendrites of the neurons 
in the neospinothalamic tract. At the same level, the axon of these neurons cross over to the 
contralateral side of the cord through the anterior commissure, and then passes up toward the brain 
in the anterolateral columns (Levene 2002). 
 
 
Figure  8. DRG in neonate and adult, from Maria Fitzgeral, The Neuroscientist 2001.  
 
 
The change in total cerebral white-matter proportion was significantly greater than the change in 
total cerebral gray-matter proportion maturation between childhood and adolescence, suggesting 
that the relative gray-matter reduction is probably due to significant increases in white matter 
(Sowell et al. 2002). 
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The balance of excitation and inhibition differs in the neonatal dorsal horn compared with that in 
the adult. Although inhibitory transmission is present, it may be less targeted in the neonate than in 
the adult. This is depicted as a possible absence of specific afferent and descending control of 
inhibitory interneurons. In the neonate, C-fibre synaptic transmission is weak and the frequency of 
miniature excitatory postsynaptic currents (mEPSCs) is low (Levene 2002). 
 
The paleospinothalamic tract transmits pain sensation from the peripheral type C fibres and some 
type Aδ-fibres. The peripheral fibres terminate mainly in laminas II and III of the dorsal horn, in an 
area called substantia gelatinosa which contains neurons with little myelin. The signal is transmitted 
to lamina V after interconnection through short interneurons within the dorsal horn. Here, the 
interneurons synapse with neurons in the paleospinothalamic tract. The axons pass through the 
anterior commissure to the opposite side of the spinal cord, and then run upwards towards the 
brain in anterolateral pathways. A few of these fibres do not cross over to the contralateral side and 
instead passes ipsilaterally to the brain. In the human, the nociceptive nerve tracts are myelinated up 
to the thalamic level at about 30 weeks (Fitzgerald 2005). 
 
Substance P 
A neuropeptide at the synapse in the dorsal horn released and metabolized slowly. Consequently, 
substance P persists after the painful stimuli, the concentration increasing, which might explain the 
progressive increase in intensity of slow-chronic pain with time (Lagercrantz 2002; Levene 2002). 
 
The flexor reflex 
At 26 gestational weeks, the human foetus/preterm infant has developed a measurable flexion 
withdrawal reflex to noxious stimuli. The threshold for these reflexes is lower, such that activation 
does not always require a noxious stimulation as in adults. The reflex muscle contractions are also 
more synchronized with a longer duration than in more mature subjects. The flexor reflex threshold 
increases with postconceptional age (PCA). Repeated skin stimulation results in considerable 
hyperexcitability or central sensitization with generalized whole body movements of all limbs. This 
phenomenon diminishes after 29-35 weeks PCA Sensitization is demonstrated by the cutaneous 
flexor reflex threshold, that is significantly reduced followed repeated pain stimuli (Andrews and 
Fitzgerald 1994; Fitzgerald 1988). 
 
Lower brain level 
The medulla, pons, mesencephalon, hypothalamus, thalamus, cerebellum, and basal ganglia are 
activated by pain at a subconscious level; these regions also control some pain reflexes without 
engaging the cerebral cortex (Arthur 1991). 
 
A few fibres of the neospinothalamic tract terminate in the reticular areas of the brain stem, but 
most fibres pass all the way to the thalamus, terminating in the ventrobasal complex with the dorsal 
column, medial lemniscal tract. A few fibres terminate in the posterior nuclear group of thalamus 
transmitted to other basal areas and the somatic sensory cortex. 
 
Only 10-25% of the paleospinothalamic tract fibres pass all the way to the thalamus. Instead these 
fibres terminate in other areas: a) the reticular nuclei of the medulla, pons and mesencephalon; b) 
the tectal area of the mesencephalon deep to the superior and inferior colliculi; and c) the 
periaqueductal gray region. These regions are all very important for the dynamic regulation of pain 
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thresholds in real-time (via spinal-brainstem-spinal loops) as well as the modulation of pain. 
Activation of the slow, chronic pain fibres in the reticular areas of the brain stem and the 
intralaminar nuclei of the thalamus is associated with strong arousal effect. This explains why an 
individual with severe pain has great difficulties to sleep (Levene 2002). 
 
Cortical level 
The cerebral cortex plays an important role for interpreting the quality of pain, whereas pain 
perception is a function of lower brain levels. Consequently, removal of the somatic sensory areas of 
the cerebral cortex does not destroy the ability to perceive pain. Recent studies suggest that early 
pain memories are not accessible to conscious recall, but may be associated with abnormal 
behavioural patterns or altered sensory processing in later life (Porter et al. 1999; Anand 2000b; 
Ruda et al. 2000). 
 
Thermal Sensation 
At least three types of sensory receptors in the skin can discriminate thermal gradation: a) the pain 
receptors, (nociceptors) are only stimulated at extreme degree of cold and heat, “freezing cold” and 
“burning hot” sensations; b) cold receptors and, c) warm receptors. There are three to ten times as 
many cold receptors as warm receptors. The receptors are stimulated by changes metabolic rates 
which are modified by the temperature described in figure 9. The thermal receptors adapt to a 
stimulus, i.e. when skin temperature decreases, the sensation is that the individual feels much colder 
than when skin temperature remains unchanged. The opposite sensation is also present, if the 
temperature is increasing a person feels much warmer than at constant temperatures (Arthur 1991). 
 
 
Figure 9. Temperature receptor response, from Guyton figure 48-10, Textbook of Medical Physiology 1991. 
 
There are four different nerve fibres that discriminate temperatures at different levels: a) pain fibres 
stimulated by cold: b) cold fibres c) warm fibres and, d) pain fibres stimulated by heat. The afferent 
thermal nerve fibres are located in deep layers of the dorsal horn in the spinal cord, parallel to the 
spinothalamic pathways that transmit pain. 
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3.4 INHIBITION OF PAIN 
The potential of the pain control system varies individually as a result of difference in the brain´s 
capacity to control the degree of afferent pain signals. The three major components included in pain 
inhibition are: a) the periaqueductal gray area of the mesencephalon and upper pons surrounding 
the aqueduct of Sylvius; b) the raphe magnus nucleus, lower pons and upper medulla. From these 
areas the signals are transmitted down in the dorsolateral columns in the spinal cord to; c) a pain 
inhibitory complex located in the superficial dorsal horn of the spinal cord. At this last point the 
analgesia signals can block the pain before it is relayed on to the brain. 
 
Several transmitter substances are involved in the endogenous analgesia system, especially 
enkephalin and serotonin. The brain opioid system operates through endorphins, dynorphins and 
enkephalins that act at multiple areas in the brain. 
 
Simons et al discuss the descending inhibitory controls are immature at birth (Simons and Tibboel 
2006). During foetal life these pathways develop in an efferent direction from the brainstem, via the 
dorsalolateral funiculus of the spinal cord, to the dorsal horn in the spinal cord. The collateral 
branches become functionally effective first at postnatal day 10 in rats (Fitzgerald and Koltzenburg 
1986). The lack of central inhibition in the immature subject leads to exaggerated and generalized 
responses to all sensory inputs, affecting low as well as high threshold stimuli. Specific pain 
responses may require convergent afferent inputs building up over time to become clinically 
apparent. 
 
Opioids 
There are three subclasses of opioid receptors (µ-, δ- and κ-receptors) within the central nervous 
system. The endogenous opioid peptides enkephalins, dynorphins and endorphins bind to these 
receptors. There is sufficient evidence that the endogenous opioid system contribute to functioning 
analgesic mechanisms in the early postnatal period (Marsh et al. 1997). The distribution of µ-opioid 
receptors has a high density the first two postnatal weeks in rat the spinal cord (Kar and Quirion 
1995; Rahman et al. 1998). The µ-opioid receptors mediate stimulation of neurotensin release in the 
PAG (Stiller et al. 1997). 
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3.5 PAIN DEVELOPMENT IN HUMANS 
 
Figure 10. Developmental stage before and after birth, from Derbyshire, et al. BMJ 2006. 
 
3.6 PAIN IN FETUS 
In uterus, the human foetus responds to pain by pronounced hormonal (Giannakoulopoulos et al. 
1994), and hemodynamic (Teixeira et al. 1999; Fisk et al. 2001) changes. When fentanyl analgesia 
was administered to the foetus during invasive procedures at 20 to 35 gestational weeks, the 
attenuated stress response to painful stimuli were seen, indicating that these responses were indeed 
induced by pain and stress (Anand and Maze 2001; Fisk et al. 2001). 
 
3.7 EFFECTS OF PAIN IN NEONATES 
Repeated skin stimulation results in hyperexcitability or central sensitization with generalized 
movements of all limbs. This phenomenon decreases after 29-35 PCA (Andrews and Fitzgerald 
1994). A neonatal animal model of persistent peripheral inflammation, exhibited spinal neuronal 
circuits with increased input and segmental changes in nociceptive primary afferent axons and 
altered responses to sensory stimulation (Anand 2000b; Ruda et al. 2000).  
 
The negative long term effects of human neonatal pain experience are described in some studies. 
Altered damped behavioural and autonomic pain scores following blood collection at 32 weeks 
postconceptional age were associated with greater numbers of experienced invasive procedures. 
Previous exposure to morphine was associated with “normalized” (i.e. increased) rather than 
diminished responses (Grunau et al. 2001). 
 
Male neonatal circumcision is associated with a greater pain response with observer VAS and 
behavioural score to routine vaccination at 4 or 6 months (Taddio et al. 1995).Topical anaesthesia, 
using  EMLA during neonatal circumcision attenuated the accentuated responses to the 
vaccination occurring 4-6 months later (Taddio et al. 1997). 
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Preterm infants following routine NICU medical care (i.e., endotracheal suctioning, chest physical 
therapy, diaper change, or nasogastric feed) were observed using the NIDCAP system. These 
procedures proceeded changes in heart rate, sleep/waking state, followed with extensor movements 
as finger splay and leg extension. Facial brow showed a function of the number of invasive 
procedures in the past 24 hours, might reflect sensitization (Grunau et al. 2000). 
 
Anand et al describe the exposure to repetitive neonatal pain may cause permanent or long-term 
changes because of the developmental plasticity of the immature brain. That human preterm 
neonate is subjected to repetitive pain during neonatal intensive care. Neonatal rat pups were 
stimulated the NICU care with needle prick and tactile stimulation, respectively. Pain thresholds 
tested with hot-plate test, withdrawal reflex, alcohol preference, air-puff startle, and social 
discrimination followed by Fos expression in the somatosensory cortex and weight gain. Tactile 
group had better weight gain. The noxious group had decreased pain latencies indicating pain 
sensitivity, increased preference for alcohol, increased defensive withdrawal behaviour, prolonged 
chemosensory memory and decreased Fos expression. These findings suggest that repetitive pain 
in neonatal rat pups may lead to an altered development of the pain system associated with 
decreased pain thresholds during development. Increased plasticity of the neonatal brain may 
allow these and other changes in brain development to increase their vulnerability to stress 
disorders and anxiety-mediated adult behaviour (Anand et al. 1999c). 
 
Research groups studying neuronal apoptosis in rodent models concluded that aesthetic agents are 
harmful for the neonatal rat brain although the current consensus is that these data do not apply to 
the developing human brain and should not alter the clinical use of Ketamine or other anaesthetic 
agents (Simons and Anand 2006; Anand 2007; Bhutta et al. 2007). 
 
3.8 PHYSIOLOGICAL ASPECTS OF NEONATAL PAIN 
Physiological indicators of pain in infants include; a) increased heart rate, respiratory rate and blood 
pressure, respectively, as well as decreased heart rate and intracranial pressure variability, 
respectively: b) decreased oxygenation and peripheral blood flow, and increased palmar sweating: c) 
autonomic changes affecting skin colour, and causing nausea, vomiting, gagging, hiccoughing, 
perspiration and dilated pupils (Stevens et al. 2000). These signs of pain have been studied in a large 
numbers of clinical settings (Quinn et al. 1992). However, isolated changes in these indicators can 
be difficult to interpret as they are also influenced by non-noxious stimuli, disease states, or 
therapeutic interventions particularly in the ill and preterm infants. Pain responses may also be 
variable in the immediate post stimulus period as a result of inconsistent and unsustainable 
activation of the immature sympathetic nervous system. 
 
Physiological indicators alone may not determine the presence or absence of pain or the efficacy of 
an intervention. In combination with other behavioural indicators of pain it will add important 
information regarding the infant’s response to acute pain. 
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Heart rate responses 
A change in heart rate (HR) is the most frequently reported physiologic indicator of pain. Significant 
increases in HR were reported as response to tissue damage at circumcision, heel lancing and 
immunization in both term and preterm infants. Significant changes in HR, mainly decreases, were 
also reported with use of analgesia and/or comfort measures during painful procedures (Grunau 
and Craig 1987; Porter et al. 1988; Grunau et al. 1990; Benini et al. 1993; Craig et al. 1993; McIntosh 
et al. 1993; 1994; Stevens et al. 1994; Taddio et al. 1995; Johnston and Stevens 1996; Taddio et al. 
1997). Endotracheal suctioning is one of the most common invasive procedures in ventilated 
preterm neonates, which may result in transiently increased or decreased HR (Simons et al. 2003). 
Heart rate variability (HRV) reduction in total HRV and power in the low frequency band in 
preterm infants occur heel lancing (Lindh et al. 1997). 
 
Oxygen saturation 
Painful procedures are associated with transient significant decreases in oxygen saturation (SaO2), 
as shown in several studies on newborn infants at different gestational age (Maxwell et al. 1987; 
Masciello 1990; Benini et al. 1993). 
 
Respiration 
A change in respiratory rate is registered in several studies, but the direction of change has not been 
consistent, in most cases an increase occurs but also a decrease and even apnoea can occur (Craig et 
al. 1993; McIntosh et al. 1993). 
 
Pain significantly affects respiration and may result in tachypnoea, apnoea and irregular breathing. 
The direction of the changes in respiratory pattern is not consistent or predictable (Craig et al. 
1993; McIntosh et al. 1993). 
 
Cerebral blood flow 
There are few studies investigating possible changes in cerebral blood flow (CBF) as response to 
pain in neonates. However, endotracheal suctioning (a procedure that has been used in several 
studies of newborns to estimate pain responses) is associated with large fluctuations in cerebral 
blood flow and oxygenation, as demonstrated by near infrared spectroscopy in preterm infants 
although the nature of these changes were related to changes in carbon dioxide levels and 
oxygenation (Shah et al. 1992; Skov et al. 1992). 
 
3.9 BEHAVIOURAL ASPECTS OF NEONATAL PAIN 
Charles Darwin described facial expressions and crying responses following pain, and took this as 
important evidence for of emotional expression in the newborn infant (Darwin 1872). Since then, 
his observations have been confirmed by a considerable amount of research. 
 
Behavioural indicators of pain include changes in facial expression, crying, body movements, and 
changes in behavioural state and functions (e.g. sleep and eating pattern). The challenge when 
evaluating newborn infants is to determine if the behaviour is specific for pain or an expression of 
discomfort, fear, fatigue, illness, or hunger (Craig et al. 1993). 
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Facial expression 
Facial activity in response to pain is less variable and more consistent in infants than crying or body 
movements (Johnston and Strada 1986; Rushforth and Levene 1994). The most frequently 
described responses to painful procedures includes specific facial actions, such as squeezing of the 
eyes, bulging of eye brows, open lips, and retraction of the upper lip causing a nasolabial furrow. 
Such facial expressions have been demonstrated in newborn infants at all gestational ages (Craig et 
al. 1993; Stevens et al. 1994; Taddio et al. 1997) as well as in older infants (Johnston et al. 1993). 
Facial activity is the most reliable and consistent indicator of pain, related to the unidimensional 
approaches across situations and populations (Grunau and Craig 1987; Grunau et al. 1990; Stevens 
and Johnston 1994) and should be considered the golden standard of behavioural responses for 
pain in infants (Craig 1998). 
 
Vocalization response 
Morphology and size of the vocal system differ between the newborn and others ages (Campos 
Banales et al. 1995). Crying is a unidimensional indicator that signals the infant’s distress to care 
providers. The quality of cry can give information about the infant’s state and biological integrity 
(Lester 1984). Crying includes several domains, e.g. fundamental frequency (pitch), cry duration, 
latency to cry, and cry intensity. Crying as a response to pain is more commonly present in term 
infants as compared to preterm infants. In very low birth weight (VLBW) infants, crying occur only 
about 50% of the time following pain (Michelsson et al. 1983; Porter et al. 1986; Barr 1993). 
 
Acoustic analysis of the infant’s vocalization response is also used frequently to assess pain and 
discomfort, mainly in research projects. Acoustic parameters that have been found to be relevant for 
estimation of pain are: the latency, the duration and the fundamental frequency (F0) of the first cry. 
Other parameters which may indicate a pain response are the chaotic changes in spectrograms from 
sound recordings (Grunau and Craig 1987; Grunau et al. 1990; Stevens et al. 1994; Michelsson and 
Michelsson 1999; Runefors et al. 2000; Runefors and Arnbjonsson 2005). 
 
Perceptual evaluation 
Clinical routinely used parameters were suggested as the F0, the pitch that correlates with F0, 
sound level (dB), aphonic/intermittent aphonics, instability, and press (Hammarberg and Gauffin 
1995; Hammarberg 2000). However, the clinical use of cry analysis is cumbersome, likely to be of 
limited benefit among preterm neonates, all mechanically ventilated neonates, or neonates with 
limited energy reserves because of critical illness. Pain cries can be identified by adult listeners as the 
most urgent and intense; cries from similarly painful procedures are judged to have the same degree 
of urgency and intensity along 3 dimensions described by the harmonic, temporal, and pitches 
characteristics of the infant’s cry (Porter et al. 1986). 
 
Body movements 
General body movements have been found to vary in response to pain, being diminished in 
preterm neonates in general, relative to full-term newborns (Craig et al. 1993). Some neonates 
respond without movements. Typical of pain responses are the finger split, leg extension in preterm 
infants (Grunau et al. 2000). 
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3.10 PAIN ASSESSMENT IN THE NEWBORN 
Pain assessment provides a clinical estimation of pain severity. The terms “pain assessment” and 
“pain measurement” are frequently used interchangeably. Although, pain assessment is a more 
comprehensive term than pain measurement, it includes both quality and quantity of pain estimates 
which can form a basis for clinical decision making. Pain measurement includes quantification and 
answers the question “how much pain?” The quality of pain, its frequency, duration, periodicity, and 
other contextual factors are included in pain assessment. 
 
Several factors contribute to difficulties in adequate pain assessment of the newborn infant. These 
include lack of basic information on the developmental neurobiology of nociception and 
pharmacokinetics of analgesics in the newborn period, combined with their inability to 
communicate verbally. That resulted in newborns often being undertreated, as they did not appear 
to experience pain. 
 
Pain assessment scales 
Pain assessment can be performed both with unidimensional or multidimensional scales. Measures 
with several composite parameters have been developed during a numbers of years for assessing 
pain in infants. Pain scales often include both physiological responses using monitor recordings or 
readings, and behavioural responses that are video-recorded or visually observed such as changes in 
facial expression, body movements and skin colour. Some of the pain assessment scales are 
developed to estimate procedural, acute pain, while some are profiled at evaluating persistent pain 
and distress. Today there are numerous mostly inadequately validated pain scales in the literature. 
The Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) (Beyer et al. 1990) was one of 
the first developed for assessing postoperative pain in children aged 1-7 years of age (Gaston-
Johansson and Asklund-Gustafsson 1985). 
 
An overview of the most commonly used pain assessment scales is given below, and also includes 
the pain scales (NFCS and PIPP) that were used in the present thesis. Scales evaluating broader 
concepts of behavioural distress in children such as anxiety, fear and/or depression are excluded 
since these scales cannot be used for assessing newborn babies. The COMFORT score (Ambuel et 
al. 1992) was organically developed to measure psychological distress in patients in paediatric 
intensive care units (PICU) patients, including newborn infants up to 24 months of age, but has 
been modified to also study pain in neonates. This scale is regarded as too complicated to use 
because of its multiple scale gradations and non-symmetric design. It includes five levels of 
responses for eight parameters, such as alertness, calm/agitation, type of respiratory response, 
movement, muscle tone, facial tension, BP and HR (Blauer and Gerstmann 1998). 
 
The Neonatal Infant Pain Scale (NIPS) (Lawrence et al. 1993) was adapted for preterm and term 
infants and includes six pain indicators, five with behavioural (facial expression, cry, arms and legs 
relaxed or tense, and arousal state) and one physiological breathing patterns. This scale is primary 
used for research purposes, although some hospitals also used it for clinical assessment of 
postoperative neonatal pain (Taylor et al. 2006). 
 
The Neonatal Facial Coding System (NFCS) is a fine grained, anatomically based measure of the 
behavioural pain response, which has consistently show high reliability, construct validity in term 
and preterm infants (Grunau and Craig 1987). The origin NFCS scale was used to describe the 
responses to acute pain occurring across different sleep/wake states, see figure 11, and included 
nine facial expressions. Later versions also differentiate acute pain from non-painful events, tissue 
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damage (painful) from non-tissue damage (stressful) phases of a procedure, therapeutic efficacy of 
pharmacologic analgesia or sucrose during invasive procedures, and non-pharmacologic 
interventions to manage pain (Grunau et al. 1990). The NFSC score decreased more following 
painful venipuncture than heel lancing (Larsson et al. 1998). 
 
Figure 11. The facial expression in two newborn infants during a heel stick, upper picture shows a 
sleeping infant with less expression and the lower pictures, an awake infant, (Grunau and Craig 
1987) from Grunau, Craig. Pain 1987. 
 
The CRIES pain scale (Krechel and Bildner 1995) is a 10-point scale similar to the APGAR score 
(Apgar 1953; Apgar and Kreiselmen 1953). This scale was developed for preterm and term 
neonates, with physiological (requires O2, HR and BP) and behavioural variables (crying, facial 
expression and sleepless) previously shown to be associated with neonatal pain following surgery. 
The CRIES scale refers to Crying, Requires oxygen for saturation above 95, Increased vital signs, 
Expression, and Sleepless. 
 
The Scale for Use in Newborns (SUN) (Blauer and Gerstmann 1998) was developed via 
comparison with NIPS and the COMFORT scales for pain assessment during four routine 
procedures (intubation, intravenous catheter insertion, endotracheal tube suctioning, and diaper 
changes). The SUN scale was a preferred tool, because it was easy to use, with scale symmetry, and 
scoring consistency. It includes seven parameters, four physiological (level of consciousness, 
breathing, heart rate, mean blood pressure) and three behavioural (movement, tone and facial 
expression). 
 
The Distress Scale for Ventilated Newborn Infants (DSVNI) (Sparshott 1995) was developed to 
assess behavioural (facial expression, body movement and colour) and physiological responses to 
painful procedures in the ventilated newborn infant. The scale is based on the Neonatal 
Behavioral Assessment Scale (NBAS) (Brazelton 1978), the Assessment of Preterm Infant´s 
behavior (APIB) (Als and Brazelton 1981), the NFCS (Grunau and Craig 1987; Grunau et al. 
1990) described above, the IBCS (Craig et al. 1984) and the Gustave-Roussy Child Pain Scale 
developed by Gauvain-Piquard in 1987. It lacks adequate psychometric validation and has limited 
clinical utility, because neonatal distress may result from pain or various other causes. 
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The Neonatal Pain Assessment Tool (Friedrichs et al. 1995), includes both behavioural and 
physiological parameters with seven items (state, cry, activity, heart rate, blood pressure, 
respiratory rate and oxygen saturation). The specific characteristic of this scale is the inclusion of 
descriptive information such as hours since the last pain medication was administered, the type 
and dose of pharmacological interventions, and the type and frequency of non-pharmacologic 
interventions. 
 
The Preterm Infant Pain Profile (PIPP) (Stevens et al. 1996) was developed to assess acute 
procedural pain in preterm and term neonates in both research and clinical practice. The PIPP is a 
measure that includes both physiological and behavioural indicators, and contextual factors (figure 
12). Each indicator is evaluated on a four point scale (0, 1, 2, and 3). Gestational age and 
behavioural state of the infant are taken into consideration in the scouring such that the total 
scores range from a total of 21 for infants of lower gestational age (GA) than week 28 and a total 
score of 18 for infants of higher GA week 36. The PIPP scale is validated for pain assessments of 
neonates at all gestational ages and is probably the most common clinically used pain scale 
(Stevens et al. 1999). 
 
 
Figure 12. The PIPP scale, from Stevens, Johnston, et al. Clin J Pain 1996. 
 
Slater et al. recently evaluated the PIPP scale using regional changes in cerebral hemodynamics, as 
measured by Near infra-red spectroscopy (NIRS). They found good correlation between PIPP 
scores and the level of cortical activity, but facial expression correlated best with cortical activity 
(correlation coefficient = 0.74; p < 0.0001). Cortical pain responses still occurred in some babies 
with no changes in facial expression and low pain scores (Slater et al. 2008), thus suggesting the 
limitation of clinical pain assessments 
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There are few scales for evaluating chronic pain and distress in newborns of different gestational 
ages. The EDIN scale (Echelle Douleur Inconfort Nouveau-Né, neonatal pain and discomfort 
scale) is a validated French scale for assessing prolonged pain in premature infants. It includes five 
behavioural indicators of prolonged pain: facial activity, body movements, quality of sleep, quality 
of contact with nurses, and consolability (Debillon et al. 2001). Although, acute pain can be 
measured reliably using a variety of methods, but measurement of chronic pain in newborns is 
difficult and is currently the focus of much research activity. For example, Boyle et al. found that 4 
factors most frequently identified babies receiving placebo analgesia: facial expressions of pain, high 
activity levels, poor response to handling and poor ventilator synchrony (Boyle et al. 2006b). 
Karolinska Hospital and Lund University Hospital in Sweden are currently collaborating in a project 
that is developing, validating and comparing two pain scales for chronic pain, with the newly 
constructed Astrid Lindgren Children’s Hospital Pain Scale (ALPS 1 and 2 for full-term infants and 
children). Another new pain scale to use in the NICU is the Behavioural Indicators of Infant Pain 
(BIIP) that combines sleep/wake states, 5 facial actions and two hand actions. In the initial study 
BIIP shows to be a reliable, valid scale for assessing acute pain in preterm infant. (Holsti et al. 
2008) 
 
3.11 TREATMENT OF NEONATAL PAIN 
Treatment of pain is a basic human right that exists regardless of age. This was stated by the United 
Nations Child Declaration of the Rights of the Child (proclaimed by General Assembly resolution 
1386(XIV) on 20th November, 1959). This is also supported by the Nordic standards for children 
and young people in hospitals and the European Association for Children in Hospital, EACH is the 
umbrella organisation for member associations involved in the welfare of all children before, during 
or after a hospital stay. Presently, 18 associations from sixteen European countries and from Japan 
are members. The Nordic EACH organisation is NOBAB, Nordiska föreningen för syke barns 
behov, an umbrella organisation with local and national representatives has the welfare of the child 
as the highest priority in Nordic paediatric hospitals and “Barnens bästa i främsta rummet” (SOU 
1997:116). 
 
Sweet solutions 
The specific mechanisms by which sweet solutions reduce pain perception in neonates is not clear; 
however the most common explanation is that the sweet solution activates endogenous endorphin 
pathways (Blass et al. 1987). Elliot Blass and colleagues are the pioneers within this research area. 
 
Sucrose 
Sucrose is a disaccharide (fructose and saccharose). The analgesic effects have been extensively 
investigated,  will only be mentioned here in brief . A Cochrane review concluded that sucrose was 
safe and effective for reducing procedural pain for single painful events in neonates. The review 
comments that use of repeated doses would need further investigation, advocates combination of 
sucrose with behavioural and conventional pharmacological measures. Sucrose treatment is 
relatively contraindicated in unstable preterm infants, or those who have conditions such as 
necrotizing enter-colitis (NEC). A commercially available 24% sucrose solution (Sweet-Ease®) can 
be given as drops, or on a pacifier. Sucrose is commonly given during or after a painful procedure to 
infants, but is not suitable as regular analgesia for ongoing pain (Stevens et al. 2004). There is an 
ongoing discussion that the fructose might act as hypersensitive allergic activator. 
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Glucose 
In Sweden glucose is more commonly used, often as a 30% solution for oral administration. This 
solution is available in the pharmacies throughout Sweden. Glucose administrated before a painful 
stimulus, reduces pain responses, i.e. decreased crying, lower HR increase and lower PIPP after 
venipuncture in newborn infants (Eriksson et al. 1999a; b). However, when parents were asked to 
grade their infants pain by VAS assessment after glucose administration, there was low agreement 
with PIPP score and cry duration (Gradin et al. 2004). No tolerance was observed after repeated 
doses with glucose 30% administration. Clinically important is that repeated doses of glucose do 
not decrease the pain-relieving effect (Eriksson and Finnström 2004). When compared to the 
local  analgesia cream EMLA, 30% glucose solution was found more effective in reducing pain 
responses, as assessed by lower PIPP scores and shorter crying time, but HR responses were similar 
in both groups (Gradin et al. 2002). 
 
Non-nutritive sucking 
Non-nutritive sucking of a pacifier has been described as a method to reduce distress during routine 
neonatal eye examination for retinopathy of prematurity (ROP). It decreases distress as assessed by 
an age appropriate, validated pain scale (PIPP), with no additional benefit from dipping the pacifier 
in sucrose (Boyle et al. 2006a). 
 
Breast milk/breastfeeding 
A Cochrane review has examined the contribution made by breastfeeding, or by administering oral 
breast milk to neonatal procedural analgesia. Neonates in the breastfeeding group had reduced heart 
rate response and reduced durations of crying, compared to the swaddled or pacifier group. 
Administration of sucrose had similar effectiveness as breastfeeding for reducing acute pain in 
neonates (Shah et al. 2006). 
 
NIDCAP and environmental 
The Newborn Individualized Developmental Care and Assessment Program (NIDCAP) is based on 
a detailed behavioural observation of the infant, which is the starting point for individualized care-
giving based on the infant's current functioning and developmental goals, which changes neonatal 
care from a protocol-based to a relationship-based care (Als and Gilkerson 1997). The NIDCAP 
also includes family support to promote the infants' medical, developmental, and emotional well-
being aspects. It has been shown that NIDCAP treatment is associated with better brain 
organization, as measured by diffusion tensor imaging MRI, and EEG (Als et al, Pediatrics 2004). In 
ex-preterm infants NIDCAP treatment was associated with a positive behavioural trend at 
preschool age (Westrup et al. 2004). Preterm infants randomized to a NIDCAP intervention during 
eye screening examinations for ROP showed similar PIPP scores as infants receiving standard care. 
However, salivary cortisol returned faster to baseline in the infants subjected to NIDCAP (Kleberg 
et al, Pediatrics 2008). Venipuncture gives less response to pain then capillary blood sampling, 
EMLA® did reduce response (Larsson 1998)   
 
Opioid Treatment 
Opiates are the most commonly used drugs for moderate and severe pain, but the correlation 
between the analgesic drug plasma concentration and validated pain scores is poor (Suri et al. 1997; 
Franck et al. 2000; Carbajal et al. 2005). 
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Morphine 
Morphine activates µ-, κ- and δ-receptors. Both the analgesic action and the respiratory depression 
that is seen following morphine administration is principally due to µ-receptor effects. Injection of 
morphine in to the peri-aqueductal grey matter has an analgesic effect, which can be inhibited if the 
descending inhibitory path is blocked, demonstrating a supraspinal site of morphine action. A spinal 
role has also been confirmed by microinjection of morphine into the dorsal horn, where it blocks 
the release of substance P (Yaksh 1997). There are also populations of peripheral opioid receptors, 
which are known to be up-regulated during acute inflammation, where topical morphine application 
could be a treatment option (Barr and Rappaport 1999; Nozaki-Taguchi and Yaksh 1999). 
 
In clinical neonatal practice, morphine has been shown to alleviate prolonged pain, reduce 
behavioural and hormonal stress responses induced by surgery or NICU care and improve 
ventilator synchrony (Quinn et al. 1992; Anand and Hall 2006). A recent meta-analysis has shown 
that morphine infusion in newborn infants may increase the number of days on mechanical 
ventilation, but that the morphine does not increase other clinical outcomes (Bellu et al. 2005). 
 
The role of morphine for treatment of acute procedural pain in newborns is not clear, as term 
neonates given intravenous morphine had similar pain scores to those that were administered 
placebo following heel lancing (Carbajal et al. 2005). 
 
In older children, as with adults, there is still some population variability in morphine effects, 
probably due to pharmacogenetic factors, with µ-receptor single nucleotide polymorphism 
accounting for some patients requiring higher opioid doses because of decreased potency of 
morphine and M6G at their receptors (Anderson and Palmer 2006). 
 
Metabolism of morphine 
Morphine is mainly metabolised by the hepatic enzyme uridine 5’-diphosphate glucuronosyl 
transferase-2B7 (UGT-2B7) to morphine 3-glucuronide (M3G) and morphine 6-glucuronide 
(M6G). M6G is a potent active metabolite, whereas M3G is inactive and even acting as an 
antagonist at high concentrations (Harrop 2007). Very preterm infants, born before 32 weeks of 
gestation excrete significant amounts of morphine unchanged in the urine as late as 24 hours after a 
single dose (Bhat et al. 1992). In acutely ill preterm infants the amount of metabolised morphine, the 
rate of renal excretion of morphine, and its metabolites exhibit wide variability. The overall trend is 
for the low neonatal clearance to increase with gestational age (Saarenmaa et al. 2000b). The hepatic 
metabolism and renal clearance may not account for all the age-related differences in morphine 
response. Data from neonatal rat dorsal root ganglion (DRG) cultures have demonstrated 
significantly more immature neurons that express functional µ-opioid receptors as compared to 
adult tissue. These µ-receptors were shown to be functional, subjected to postnatal development 
and probably account for the lower opioid requirements of preterm infants (Nandi et al. 2004). 
 
The metabolism of opioids is immature in newborn infants. The volumes of distribution, drug 
clearances, side-effects and drug efficacy all differ in newborns as compared to older children and 
adults (Simons and Tibboel 2006). Systems for drug clearance and metabolic pathways begin to 
develop during foetal and early postnatal period, reaching adult levels after months and years (Bhat 
et al. 1992; Hartley et al. 1993; Barrett et al. 1996; Scott et al. 1999; Saarenmaa et al. 2000a; 
Bouwmeester et al. 2004). 
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Side- effects from opioid treatment 
The arguments against treatment of neonatal pain with opioids includes uncertainty about opioid 
side effects, increased risk at higher doses and frequency, particularly in the preterm neonates since 
adverse effects also include hypotension (Hall et al. 2005), respiratory depression, urinary retention, 
nausea/vomiting, constipation, increased risk of necrotizing enterocolitis, and others are reported in 
the newborn infants (Anand et al. 2004). Very little is known about side effects from repeated 
opioid administration, or specific safety issues of opioids when treating critically ill, neurologically 
impaired, congenitally malformed, or other special populations of neonates (Simons and Anand 
2006). 
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4 AIM 
The overall objective of this thesis was to investigate factors alerting pain responsiveness in the 
newborn infant from a physiological and developmental perspective, and to evaluate effects of 
opioid analgesia in the mechanically ventilated preterm infant. 
 
 
The specific aims of the studies included are: 
 
• To assess effects of pre-emptive analgesia with morphine in preterm infants following 
medical care at the NICU within the NEOPAIN project, (Papers I, II and IV). 
 
o To investigate short-term outcomes with regard to the incidence of severe IVH 
grade III and IV, PVL and neonatal death, (Paper I). 
 
o To compare pulmonary outcomes with relation to morphine treatment, (Paper II). 
 
o To examine the ability of neonatal staff to estimate analgesia treatment in preterm 
infants, (Paper IV). 
 
• To record cortical activation in preterm infants following tactile and painful stimulation 
sequentially, and to identify the factors modifying neonatal responses, (Paper III). 
 
• To measure the responses following graded painful stimulation in the preterm and term 
newborn infant, (Paper III and V). 
 
• To study developmental changes in the neonatal pain response during the first hours 
following birth in relation to the type of delivery, (Paper V). 
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5 METHODS 
5.1 STUDY DESIGN 
Study I – NEOPAIN Trial, primary outcome 
The aim of the NEOPAIN trial (Neurologic Outcomes and Pre-emptive Analgesia in Neonates) 
was to investigate if pain treatment with morphine reduces early neurological injury in ventilated 
preterm infants. The primary outcome was defined as a composite outcome (including neonatal 
survival and absence of IVH grade III-IV or cystic PVL). 
 
The NEOPAIN study is a multicenter randomized controlled trial comparing pre-emptive 
morphine infusion with placebo. A total of 898 neonates from 12 American and four European 
centres were included in the study, (including 73 infants from Sweden, 58 at Karolinska University 
Hospital and 15 at Örebro at University Hospital). 
 
Inclusion criteria were: birth at 23-32 weeks of gestation, intubation within 72 h after birth, and 
mechanical ventilation for less than < 8 hours. Exclusion criteria were: major congenital anomalies, 
birth asphyxia, intrauterine growth retardation, maternal opioid addiction, and neonate’s 
participation in other clinical trials. 
 
The power estimation was based on results from a previous pilot study (Anand et al. 1999a) and 
hypothesized that morphine analgesia would reduce the composite primary outcome from 25.0% 
to 17.5%. Sample-size calculations showed that 470 neonates were needed in each group to test 
this hypothesis with α=0.05 and 80% power, assuming complete follow-up. 
 
Infants were randomized to receive either morphine or placebo (dextrose 5%) in a blinded fashion. 
To ensure equal numbers in each group, randomization was stratified by the participating NICU 
and by their gestational age at birth (23-26, 27-29 and 30-32 weeks). 
 
Neonates assigned to the morphine group received a loading dose of morphine 100 µg/kg infused 
during 1 hour, followed by continuous infusions of 10, 20 or 30 µg/kg/h, depending on the 
gestational-age group, see table 2. 
 
Table 2. Number of included infants and morphine dosing, modified from Anand, Bergqvist, et al. Lancet 
2004. 
 
GA 
WEEKS 
PLACEBO 
GROUP 
MORPHINE 
GROUP 
MORPHINE 
LOADING DOSE
MORPHINE 
MAINTENANCE DOSE 
23-26 174 176  
100 µg/kg 
10 µg/kg/h 
27-29 190 190 20 µg/kg/h 
30-32 83 85 30 µg/kg/h 
 
The study was designed for weaning and stopping the study drug, if extubation was expected within 
24 hours, no spontaneous respiration was present at paCO2 5.3-6.7 kPa, rapid deterioration in the 
clinical condition, and after maximum 14 days of the study drug. Protocols for weaning the study 
drug were designed, to avoid opioid withdrawal. Guidelines included issues as; additional 
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administration of analgesia and sedative drugs, dosing and drug interactions (muscle relaxants, 
opioid antagonists, anticonvulsant therapy), for example, use of midazolam and other sedative or 
analgesic drugs were not allowed; criteria for weaning and stopping the study drug, with opioid 
weaning to avoid drug withdrawal symptoms; interactions with other therapeutic interventions as 
type of environmental and nursing such as enteral nutrition. 
 
 
Figure 13. CONSORT diagram showing the inclusion of patients in the NEOPAIN trial, from 
Anand, Bergqvist, et al. Lancet 2004. 
 
In view of ethical concerns related to having a blinded placebo group, intermittent boluses of open-
label morphine (AA) were allowed in both groups, on the basis of specific criteria and given as 
intermittent boluses as decided by the treating physician at each NICU. 
 
Since endotracheal suctioning is one of the most common invasive procedures in ventilated 
preterm neonates, the response to endotracheal suctioning was assessed with pain scores (PIPP 
and COMFORT) and HR changes from before to 2 minutes after suctioning. This assessment 
was done before the start of the study drug infusion, and at 24 h and 72 h during infusion and at 
12 h after the end of the infusion. 
 
Data collection included baseline clinical and demographic characteristics: GA, BW, Apgar score, 
the Clinical Risk Index for Babies (CRIB), presence/absence of respiratory distress syndrome 
(RDS), air leaks (pneumothorax, pulmonary interstitial emphysema etc) and patent ductus arteriosus 
(PDA), surfactant treatment, results from repeated cranial ultrasonography, sepsis, 
bronchopulmonary dysplasia (BPD),  neonatal medical index (NMI) duration and type of ventilator 
support and numbers of days with hospital care. 
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Study II – NEOPAIN Trial, pulmonary outcomes 
The aim of Study II was to evaluate pulmonary outcomes in relation to the study drug 
(morphine/placebo) in the NEOPAIN trial, secondary analysis. The neonates included in Study II 
were the same infants as in Study I. 
 
The power calculation was based on an assumption that the incidence of BPD in the target 
population (23–32 weeks of gestation) was 30%. Three-hundred and seventy infants in each group 
would allow us to detect a change in BPD of at least 30% with α=0.05 and a power of 0.8.  
 
Data collection included baseline clinical and demographic characteristics, vital signs, and clinical 
outcomes related to ventilator management. 
 
There were no specific guidelines for extubation in the NEOPAIN protocol; however, most of the 
participating centres used the following criteria for extubation: 
- Peak inspiratory pressure of ≤16 cm H2O 
- Positive end expiratory pressure of ≤5 cm H2O 
- Intermittent mandatory ventilation rate of 15 to 25 breaths per minute 
- Fraction of inspired oxygen of ≤0.35 
 
Table 3 Maternal and Infant characteristics in the NEOPAIN study. Numbers are number 
(percents) unless stated, modified from Anand, Bergqvist, et al. Lancet 2004. 
  
 MORPHINE 
(N = 449)
PLACEBO 
(N = 449)
P-VALUE 
Maternal age, y, mean (SD) 26.8 (6.6) 26.5 (6.3) 0.55
Maternal race, white 273/446 (61.2) 262/448 (58.5) 0.52
Maternal chorioamnionitis 62/446 (13.9) 54 (12.0) 0.41
Maternal antibiotics 276/446 (61.9) 288/447 (64.4) 0.43
Prenatal steroids 364/444 (82.0) 364/445 (81.8) 0.94
Gestational age, w 27.3 (2.3) 27.4 (2.3) 0.80
Birth weight, g 1037 (340) 1054 (354) 0.46
Apgar score at 1 min 5 (3–7) 5 (3–7) 0.66
Apgar score at 5 min 7 (6–8) 7 (6–8) 0.97
 
Definitions of neonatal and maternal variables are available in the publication, paper II. 
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Study III – Cortical activation from pain  
The primary aim was to investigate whether newborn infants demonstrate cortical activation as a 
response to pain. The study included 40 vaginally delivered newborn infants who required blood 
sampling in the NICUs at Karolinska University Hospital (Stockholm, Sweden) and Gaslini 
Hospital (Genova, Italy). 
 
Inclusion criteria were: birth after 26 weeks of gestational and >24 hours postnatal age. Exclusion 
criteria were: congenital malformations affecting cerebral circulation or the cardiovascular system; 
ongoing intubation or mechanical ventilation; administration of analgesic, anaesthetics, and/or 
sedatives drugs within 24 hours prior to the study. 
 
A total of 40 infants at 28 to 36 weeks of gestational age were included. Their postnatal ages 
ranged from 25 to 42 hours. The duration of pain stimulus (routine venipuncture) was 48.3 (35 to 
60) seconds. 
 
Figure 14. Patient flow diagram, from Bartocci, Bergqvist, et al. Pain 2006. 
 
A double-channel NIRS device (NIRO 300, Hamamatsu Photonics, Hamamatsu, Japan) was used 
to monitor changes in cerebral oxy-hemoglobin [HbO2], deoxy-hemoglobin [HbH], and total 
hemoglobin [Hbtot] concentrations. Briefly, the NIRO 300 produces light at four different 
wavelengths (775, 810, 850, and 910 nm). Each diode has a pulse frequency of approximately 2 
kHz that lasts about 100 ns, the average output power is about 1 mW. The emitter and receiver 
probes constitute one pair of optodes. Through an optical fibre cable, the emitter probe submits 
near infrared light, which is reflected in brain tissue and detected by the receiver probe (Wyatt et 
al. 1990). 
Figure 15. The figure shows the position of the NIRS optodes (E, emitter; R, receiver), viewed with 
reference to a coronal section of the brain. The dashed areas illustrate cortical regions that are 
illuminated by the near infrared light, from Bartocci, Bergqvist, et al. Pain 2006. 
R
E
R
E
Cortical areas illuminated 
by NIRS
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In the preterm newborn brain, with a thinner cortical mantle and lower tissue density (scalp, skull, 
dura, and brain), the infrared light may penetrate relatively deep, and measure tissue light absorbance 
within the primary somatosensory cortex and parts of the secondary somatosensory cortex, the 
insula, and cingulate cortex. 
 
The two pairs of optodes were positioned over the somatosensory cortex symmetrically on each 
side of the head. Eleven newborns were monitored with the two pairs of optodes placed on the 
same side of the head: one pair overlying the somatosensory cortex and the other pair overlying 
the occipital cortex. In these newborns, the tactile and painful stimuli were applied contralaterally 
to the side where the optodes were placed. 
 
The NIRS measurements were performed in three phases at venous blood sampling: Phase 0 was 
a 60 seconds baseline; phase 1 included a tactile stimulus, the skin disinfection during 30 seconds 
and phase 2 included the painful stimulus, i.e. venipuncture, see figure 16. 
 
 
 
 
Figure 16. This figure describes the study procedures with the three phases of the study. Modified 
figure from Bartocci, Bergqvist, et al. Pain 2006. 
 
Heart rate, oxygenation and respiration were recorded by a HP monitoring system (Hewlett–
Packard, Boeblingen, Germany) simultaneously with the NIRS data. Respiration was observed 
during the procedure. HR and SaO2 average values were averaged at baseline and at 10, 20, 30, 40, 
50, and 60 s after the tactile and painful stimuli, respectively. 
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Study IV – NEOPAIN Trial, Seeing through the blind! 
The aim of this study was to evaluate if neonatal staff can assess whether ventilated preterm infants 
receive morphine or placebo. The included infants were a subcohort of the NEOPAIN from study 
I in this thesis. 
 
The neonatal staffs’ nurses and physicians were asked to fill in an assessment form when a newborn 
infant was enrolled in the NEOPAIN trial at the two Swedish centres, Karolinska University 
Hospital and Örebro University Hospital (Stockholm and Örebro). The staff participation was 
voluntary and the assessment form was filled in anonymously. 
 
The entire form included five questions: 
1. Profession (assistant nurse, registered nurse or physicians) 
2. Duration of NICU experience (<1, 1-5 or >5years) 
3. Gender (woman or man) 
4. Which randomisation group (morphine and placebo) does the neonate belong to? 
5. Does the neonate have sufficient analgesia (yes or no) 
 
A total of 516 assessment forms were distributed (Stockholm 371 and Örebro 145), and 360 forms 
were returned and analyzed. Stockholm collected 288 assessment forms on 43 neonates, and Örebro 
contributed with 72 forms on nine neonates, see table 4, the described definition of the qualitative 
and quantitative factors assessed in this study. 
 
Table 4. Factors in the study, including definitions of qualitative and quantitative variables. Modified 
from Bergqvist et al. Acta Paediatrica 2007. 
 
CLINICAL FACTORS DEFINITION 
Qualitative  
Profession  
Education Physician vs. nurse vs. assistant nurse 
Experience at NICU <1 vs. 1-5 vs. >5 years 
Neonates  
Treatment group Continuous morphine analgesia vs. placebo 
Gender Female vs. male, genitalia on physical examination 
GA group 23-26 vs. 27-29 vs. 30-32 weeks 
CRIB score Total score (1-20) from the “Clinical Risk Index for Babies”, with 10 as the reference score
Quantitative  
CRIB score Total score (1-20) from the “Clinical Risk Index for Babies”, as continuous variable. 
NMI score Total score from the “Neonatal Medical Index” 
Days of ventilation Number of intubated days with ventilated support by CMV and HFOV  
Level of morphine Plasma level at 24 hours after study drug started (ηg/ml). 
Additional analgesia morphine before Amount of additional morphine (mg/kg) given before the started study drug  
Additional analgesia morphine during Amount of additional morphine (mg/kg) given during study drug 
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Study V: Mode of delivery affects Pain Responsiveness 
The aim of this study was to evaluate if the mode of delivery affected pain responsiveness in term 
infants during the first hours after birth. 
 
Women admitted to the delivery ward at Karolinska University Hospital with spontaneous 
vaginally delivery (VD) or planed elective caesarean section (CS) were asked to allow their 
newborn infant to participate in this trial. 
 
Inclusion criteria were: full-term birth (VD or CS) following an uncomplicated pregnancy, 37 to 
42 weeks of gestation, and appropriate weight for gestation (AGA), Apgar score of ≥ 7 at 5 
minutes after birth, and normal physical appearance. Exclusion criteria were: premature rupture of 
membranes, labour lasting longer than 24 hours, infants delivered by vacuum extraction or acute 
CS, and infants of mothers who required epidural anaesthesia or pudendal nerve block. 
 
For the included subjects, all elective CS were performed under spinal anaesthesia using 
bupivacaine with the mothers being awake during the surgical procedure, while analgesia during 
VD was achieved with 50% N2O. Infants born after VD (N=53) and elective CS (N=23) were 
similar with respect to gender, birth weight and postnatal age (in minutes), although infants born 
after elective CS had lower GA, for detailed description see, publication. 
 
Heart rate was recorded with standard electrocardiogram (ECG), with a sampling frequency of 1000 
Hz (BIOPAC). The signal was digitized and displayed in real-time using the AcqKnowledge 
software. The baseline HR in beats per minute (bpm) was evaluated during a 1-minute reference 
period immediately before the stimulus. Directly following stimulation, the HR was measured at 1-
second intervals for a period of 10 seconds; these readings were averaged and then expressed as a 
percentage of the baseline HR (HR %). 
 
The study procedure included assessments of infants’ responses to three standardized stimuli, one 
painful and two cold stimuli. Our high-intensity pain stimulus was the routine intramuscular 
injection of vitamin K. After 2 min, the low-intensity stimulus, a cooled metal spoon was applied on 
the abdominal skin for 10 s. After further 2 min, 10 drops of cold water were dropped at the infant 
foot. This sequence of stimulation was the same for all infants, and no stimulus was repeated. 
Infants were randomized to receive these stimuli either within >30 to ≤90 or at >90 to <260 min 
after birth and were evaluated by blinded observers. 
 
As behavioural response we used facial expression as estimated with the NFCS (Grunau et al. 1990). 
The NFCS score was evaluated during the first 15 s immediately following each of the three stimuli. 
Collected data were coded and trained staffs estimated independently each of the seven facial 
expressions second by second. The analysis of the video tapes was performed by a slow motion 
with frequent stops and 10% were studied repeatedly to confirm reliability. 
 
Infant’s vocalization was recorded by a Digital Audio Tape recorder with a microphone at a distance 
of 15 cm from the infant mouth. Background sound in the room was monitored and maintained at 
or below 60 dB and all recordings were calibrated. Vocalizations were analyzed for both acoustical 
and perceptual features with a computerized voice analysis program (Swell). Vocalization occurring 
within 30 s from each stimulus was included in this analysis, with a primary focus on the first five 
expiratory vocalizations and total number of inspiratory vocalizations. Acoustical analysis includes 
the quantitative and qualitative aspects of infant vocalization. 
Acoustical parameters analyzed within the first 30 s from stimuli: 
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1. Time to response, from start of applied stimuli to start of vocalization. 
2. Time of vocalization, total duration of expiratory and inspiratory vocalization. 
3. Total time of vocalization, including pause. 
4. Sound intensity in decibel (dB). 
5. F0 the strongest of the first five vocalizations. 
 
Perceptual analysis was performed by six listeners (three midwives and three speech therapists) with 
experience in professional sound judgment. The VISOR program was used for individual training 
session. The five expiratory phonation’s were compressed in the Swell program with the GLUE 
subprogram to create a listener's test. Each listener received an individual training session with six 
vocalizations and used the VISOR program in the evaluation (Granqvist and Hammarberg 2003). 
 
Table 5. Six perceptual parameters were selected for the evaluation; the assessments were graded 
using visual analogue scales (VAS), Modified from Bergqvist et al. Acta Paediatrica 2007. 
 
Parameter Estimation Scale 
Type of vocalization Cry or grumble Classification 
Level of pain Non to severe VAS 
Pitch Low to high VAS 
Sound level Weak to strong VAS 
Instability Non- to very much VAS 
Press Non to very much VAS 
 
The included parameters are used routinely in clinical voice estimation (Hammarberg 2000). The 
listeners were instructed to classify the infant's vocalization and assign a numeric value on a visual 
analogue scale (VAS) marked from 0 to 1000, see table 5. 
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5.2  STATISTICS 
Study I – NEOPAIN Trial, primary outcomes 
Since the NEOPAIN study was blinded, coding and data analyses were performed at Maryland 
Medical Research Institute, USA. All analyses were by intention to treat. Group outcomes were 
compared by χ2 tests or Fisher’s exact tests and homogeneity of the odds ratios across gestational 
ages was tested by the Breslow-Day test. Logistic regression models were used to predict each 
outcome. All analyses were done with SAS software (version 8.1), the p-value was set at α=0.05. 
Results of logistic regression analyses are presented as point estimate odds ratios with two-sided 
95% CI. Pain assessments and vital signs were compared between the randomized groups by use 
of Student´s t-tests. 
 
Study II – NEOPAIN Trial, pulmonary outcome 
Treatment group demographic features and outcomes were compared with Student’s t-test, χ2 
tests, or Fisher’s exact tests. For data that did not have a strictly normal distribution, the results 
are presented as median and interquartile ranges, and nonparametric tests (Wilcoxon test and 
Kruskal-Wallis test) were used for analyses as appropriate. Multiple linear regression models were 
used to evaluate effects from various clinical variables, days on ventilation support, nCPAP, and 
oxygen treatment, as well as the length of stay at hospital. The multiple linear regression models 
are presented as parameter estimates and SEs. Factors associated with the outcomes of pulmonary 
air leaks, BPD, and BPD or death was analyzed with logistic models. The fit of each logistic 
model was assessed with the Hosmer-Lemeshow goodness-of-fit test, and the global test that all 
regression parameters were 0 was tested with the -2 log-likelihood statistic. Results of these 
analyses are presented as odds ratios with 2-sided 95% confidence intervals. All analyses were 
performed with SAS statistical software (SAS Institute, Cary, NC), with the critical p-value set at 
α=0.05. 
 
Study III – Cortical activation from Pain 
The repeated-measures ANOVA and Newman–Keuls post hoc tests were used for comparisons 
between P0, P1 and P2 responses for [HbO2], [HbH], and [Hbtot] respectively. Student’s t-tests for 
independent variables were used to compare [HbO2]diff values between the parietal and occipital 
cortex (in neonates where both sets of optodes were positioned contralateral to the stimuli), to 
compare [HbO2]diff values between the ipsilateral and contralateral side, to evaluate inter-
hemispheric differences depending on whether the left or the right hand was stimulated, and to 
compare the differences between male and female infants. Correlations between GA, BW, PNA, 
and duration of the venipuncture, and magnitude of the NIRS response were performed by linear 
regression analyses. Data were analyzed by the program Statistica® , critical p-values at α=0.05. 
 
Study IV – NEOPAIN, Seeing through the blind! 
The estimation of the suggested study drug assessment were analysed by one-sample tests of 
binominal proportions, and proportions between groups with χ2-test. Effect of education and years 
of experience were analysed using the logistic regression model with Fisher’s scoring. The fit of each 
logistic model was assessed using the Hosmer–Lemeshow, goodness-of-fit test and the global test 
that all regression parameters are zero and tested using the 2-log likelihood statistic. Results of 
logistic regression analysis are presented as p-values and odds ratios (OR) with two-side 95% 
confidence intervals (CI) to show the effect of each predictor variable on the indicated outcome. 
The entire analyses were performed using SAS statistical software (Cary, NC) and the critical p-value 
was set at α=0.05.  
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Study V – Mode of Delivery affects pain responsiveness 
Power was calculated to indicate a 20% difference in response to the stimuli within the two modes 
of delivery. As the group of patients was small, nonparametric statistics were used. The possible 
differences between responses to high-intensity (injection) and low-intensity (two cold stimuli) 
stimuli were analyzed by Kruskal–Wallis analysis of variance. 
 
The Statgraphics Plus software was used to analysis these data. Correlation between change in HR 
(%) in response to stimuli and postnatal age (in minutes) of infants was analyzed by linear 
regression. Relationship between the predictors’ independent variables (birth weight, gender, 
mode of delivery and postnatal age in minutes at stimulation) and dependent variable (change in 
HR, facial expression, and vocalization) were examined in two steps. First, all possible correlations 
between the variables were analyzed (Spearman’s rank correlation coefficient). Variables that were 
significantly correlated with the predictor (p<0.05), were analyzed for independent association 
using stepwise multiple regression analysis (backward selection). 
 
The perceptual estimation of pain intensity using VAS in relation to qualities of vocalization such 
as pitch, intensity, instability and pressure were evaluated by linear regression analysis. Correlation 
between the two NFCS observers and the six perceptual listeners was analyzed to calculate the 
inter-rater reliability of these methods. 
 
5.3  ETHICS 
The ultimate participation of human subjects cannot be avoided in biomedical research, because the 
conclusions drawn from animal experiments may not apply to human genetics, development, 
behaviour, or the susceptibility, aetiology, epidemiology, pathophysiology, and management of 
human diseases. 
 
The potential costs to a human subject are balanced against potential benefit, either to that 
individual or to society at large. For newborns, there is no possibility for them to conduct their own 
risk-benefit analysis with regard to participating in research, and thus extra attention must be paid to 
ensure that this vulnerable population is not exploited. The major issues related to including infants 
in research focus on the process of consent, assessment of risks and benefits, the use of placebo 
controls, and the inclusion of healthy subjects (Kauffman 2000). 
 
In the case of analgesic studies, costs to the subject might include: 
• Withholding of analgesia. This is of concern when placebos are introduced and it would be 
important that participation in the study would expose the child to no more pain that what 
is dictated by the clinical standard. 
• Unknown side-effects. Especially in studies of safety, there must be means available to address 
or reverse effects of the study medications. 
• Additional burden related to monitoring. Blood sampling of drug level and pharmacokinetic was 
and is a key issue for young premature infants. 
 
Consent issues 
Because infants are incapable of being involved in the consent process, a surrogate, usually a parent 
provides permission on their behalf. There is thus a clear assumption that this surrogate is 
competent to understand the issues and that the surrogate is only operating in the best interests of 
the child. Issues pertaining to the care of neonates are complicated and presentation of a research 
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protocol to parents under emotionally stressful circumstances may prevent the clarity of thought 
and a thorough cost-benefit analysis. Furthermore, when there are inducements for participation in 
a study, one cannot take for granted that all decisions are made purely on behalf of a child’s best 
interests. 
 
Risk-Benefit Analysis 
Risk-benefit analysis has been divided into four major categories: (a) research not involving greater 
than minimal risk, (b) research involving more than minimal risk with the prospect of direct benefit 
to the child, (c) research involving more than minimal risk with no direct benefit but likely to yield 
important generalized knowledge, and (d) research not otherwise approvable that presents an 
opportunity to understand, prevent, or alleviate a serious problem affecting the welfare of children 
(Kauffman 1995). 
 
Although some clinicians may advocate that young children should only participate in studies that 
pose less than minimal risk or studies that provide direct benefit to the participant (Burns 2003), 
however, the American Academy of Paediatrics (AAP) urges for a broader interpretation of benefits 
to include those which will advance the welfare of children in general (Kauffman 1995). Further, 
when evaluating benefits and risks, the benefits to children arising from being included in clinical 
research versus the risks of not doing the research in infants and children should be considered, in 
addition to the direct and immediate risks and benefits to individual subjects. The AAP also pointed 
out that risks may be minimised by limiting the number and type of invasive tests, improving or 
developing non-invasive and safe methods of monitoring biological effects, and by fully preparing 
and informing subjects about the proposed study procedures (Kauffman 1995). 
 
A major concern in the context of analgesic trials in children is the additional burden related to 
monitoring drug levels or diagnostic tests for side effects. Blood sampling in drug level and 
pharmacokinetic studies is a key limiting factor in very premature infants. Total blood loss should 
not exceed 2% of the estimated blood volume of a patient with normal red blood cell mass. If one 
assumes that blood volume is 80 ml/kg of bodyweight, small premature infants may be exposed to 
the risks of serious depletion, especially if an array of diagnostic blood tests is performed in addition 
to a research-related blood sample. Novel strategies, such as scavenging the blood drawn for other 
reasons may become imperative as a way to gather the desired data. Finally, blood and urine 
sampling itself will not be invasive if established clinical catheters will be used to draw samples. 
 
Drug studies in neonates 
Many drugs used to treat children have never been evaluated in children. None of drugs is registered 
within EU regarding EMEAs guidelines, presented by Agnes Saint Raymond, the head of Sector 
Scientific advice. The neonatal age represents the period of life when the most profound and rapid 
physiological changes occur. Thus, the population as a whole is very heterogeneous. Population 
based approaches for drug evaluation offers the ability to address the effects of covariates and 
estimate inter-individual variability in pharmacokinetics and dosing (Jacqz-Aigrain and Burtin 1996). 
 
Investigation must try to minimise anaemia and pain from blood draws while obtaining data from 
neonates who require specific medications for their survival and care. There is also the potential for 
rapid changes in clinical status of NICU patients that may affect pharmacology of analgesia (clinical 
diagnosis: multi-organ system illness affecting hepatic blood flow, dehydration, plasma protein 
levels, nutritional state, drug interactions etc). 
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Safety issues 
Neonatology is replete with examples of harm from therapeutic misadventures due to lack of 
adequate clinical studies. Before interventions become commonplace, proper evaluation of safety 
and efficacy are needed. Safety is best assessed in studies where monitoring guidelines are pre-
specified and adhered to in the protocol. It is not easy to identify a-priori all infants at risk of 
adverse effects so all infants must be carefully and thoroughly evaluated to detect risks.  
 
Investigations must include determination of immediate and longer term safety. In order to evaluate 
safety, there should be a clear understanding of the relationship between pharmacokinetics and 
pharmacodynamics, such that drugs are studied for a sufficient time period for their pharmacologic 
effects to be observed. If drugs are to be used repeatedly, then additional determinations of the 
time-course of effects are needed for defining the optimal dose and dosing interval. Biologically-
based outcomes should be evaluated.  
 
Although neonates may have the highest incidence of adverse events in part due to underlying 
morbidity, this must be weighed against the need to provide analgesia. 
 
Ethical compliance 
The ethical issues in these projects have been scrutinized by local and regional research ethics 
committees, and ensure compliance with: 
• Ethical standards of local and regional ethical committees. 
• Decisions and requirements of local and regional ethical boards. 
• The Amsterdam protocol on animal protection and welfare. 
• The World Medical Association with Helsinki Declaration, 2000 and its amendments. 
• Universal Declaration of Human Rights, 1948. 
• UN Convention on the Rights of the Child, 1989. 
• The Convention of the Council of Europe on Human Rights and Biomedicine (Oviedo, April 
1997).Universal Declaration on the Human Genome and Human Rights adopted by UNESCO, 
1997. 
• The CIOMS (Council for International Organizations for Medical Sciences) International Ethical 
Guidelines for Biomedical Research Involving Human Subjects, 2002. 
• The World Health Organization, Guidelines for Good Clinical Practice for Trials on 
Pharmaceutical Products, 1995. 
• The International Conference on Harmonisation (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use with Guidelines for Good Clinical Practice, 
1996. 
• The Charter of Fundamental Rights of the EU. 
• The EU Clinical  Trials Directive 2001/20/EC of the European Parliament and of the Council 
of 4 April 2001 on the approximation of laws, regulations and administrative provisions of the 
Member States relating to the implementation of good clinical practice in the conduct of clinical 
trials on medicinal products for human use. 
• Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the 
protection of individuals with regard to the processing of personal data and on the free 
movement of such data. 
• Council Directive 83/570/EEC of 26 October 1983 amending Directives 65/65/EEC, 
75/318/EEC and 75/319/EEC on the approximation laid down by law, regulation or 
administrative action relating to proprietary medicinal products. 
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• Convention of the Council of Europe on Human Rights and Biomedicine signed in Oviedo on 4 
April 1997. 
• Swedish Code of Statutes 2003:460 and 2003:615 on ethical review regarding research involving 
humans. 
 
Protection of human subjects 
We have strictly complied with widely recognised international texts and codes of practice (as listed 
above). The projects have respected all ethical requirements in objectives and methodology, and 
there are no known negative ethical implications of the results to be obtained. Only after obtaining 
written consent from parents, patient’s blood samples or other data were collected without causing 
additional pain. All specimens and research records were coded to protect the identity of patients 
and to ensure confidentiality. Patients have been recruited in a consecutive manner without regard 
to race, gender, social class or other considerations. Patient data have been obtained through 
medical record chart review and interviews, while avoiding any personal identifiers. We have assured 
confidentiality by using codes for patient identification, and confidentiality laws will be strictly 
observed when processing human clinical information. No patient identifying information was or 
will be published, or to be available after the requisite clinical data have been collected or published. 
Data have been accessible only to members and coordinators of the participating facility and 
research team, which will include pathological and medical personnel under approved guidelines. 
The data registers were designed and kept according to applicable legislation. The content of data 
collection were and will be reported to authorities, from where the parents have possibility to 
request information. These clinical trials of drugs have been conducted in compliance with the 
Helsinki Agreement and only after approval by the local ethics committee at each site. 
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6 RESULTS 
6.1 STUDY I – NEOPAIN TRIAL, PRIMARY OUTCOMES 
Primary outcome 
When data from all infants were analysed, there were no differences in the composite outcome or its 
components (neonatal death, severe IVH, or PVL) between the two randomised groups, see table 6. 
However, at 27 to 29 gestational weeks, the proportion of infants with severe IVH was higher in the 
morphine group than in the placebo group, and the difference in the frequency of the composite 
outcome almost reached statistical significance. On the other hand, there were no significant 
differences in neonatal death, severe IVH and PVL or the composite outcome at 23 to 26 and 30 to 
32 gestational weeks. 
 
Table 6. Primary outcomes for all included neonates in the NEOPAIN trial, Modified from Anand, 
Bergqvist et al. Lancet 2004. 
 
OUTCOME MORPHINE 
(%)
PLACEBO 
(%)
P-VALUE 
Overall
Severe IVH 13 11 0.24 
PVL 7 9 0.35 
Death 13 11 0.25 
Composite 27 26 0.58 
23 to 26 weeks 
Severe IVH 20 20 0.95 
PVL 6 10 0.26 
Death 26 24 0.58 
Composite 40 42 0.70 
26 to 29 weeks 
Severe IVH 12 6 0.04 
PVL 9 7 0.44 
Death 5 3 0.31 
Composite 23 15 0.053 
30 to 32 weeks 
Severe IVH 3 2 0.99 
PVL 4 13 0.07 
Death 2 - - 
Composite 10 15 0.31 
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Table 7. Factors associated with the primary outcome and its component (all infants), Modified from 
Anand, Bergqvist et al. Lancet 2004. 
 
 RELATED TO NOT RELATED TO 
Neonatal death Gestational age Treatment group 
 CRIB score  
Severe IVH Gestational age Treatment group 
 CRIB score  
 Maternal race  
 Lack of antenatal steroids  
PVL Maternal chorioamnionitis Treatment group 
  Gestational age 
Composite outcome Gestational age Treatment group 
 Male sex  
 Lack of antenatal steroids  
 Severity of illness - NMI  
 Maternal chorioamnionitis  
 
 
PIPP 
The PIPP score response to endotracheal suctioning was significantly lower in the morphine group 
than in the placebo group at 24 h after initiation of study drug. The mean (SD) PIPP was 8.00 (2.69) 
in the morphine group versus 8.77 (3.18). 
 
 
 
Figure 17. The table shows mean (SD) changes in PIPP during endotracheal suction in neonates 
receiving morphine (darker bars) vs. placebo (light grey bars), from Anand, Bergqvist, et al. Lancet 2004. 
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Hypotension 
Before start of the study drug infusion, arterial hypotension was present in 86/449 infants in the 
placebo group and in 103/449 infants in the morphine group (20.0% vs. 23.8%, non-significant 
difference). Hypotension was significantly more common in the morphine group than in the 
placebo group, after the loading dose and at 24 h of study infusion, see figure 18. After the loading 
dose, 26 infants in the morphine group and 13 in placebo group developed hypotension. 
Figure 18. Incidence of clinically hypotension in relation to study drug infusion, from Anand, Bergqvist, 
et al. Lancet 2004. 
 
Other side effects 
Neonates in the morphine group had a longer duration of mechanical ventilation but required 
similar duration of oxygen therapy.  Neonates in the morphine group took longer time than the 
placebo group to tolerate full-volume nasogastric feeds but achieved full volume oral feeds at the 
same time period (see Figure??). The need for bladder catheterisation (placebo group 22, morphine 
group 35) was not significantly different between the two groups (p=0.084).  
 
Open label morphine 
The decision to use open-label morphine was based on the clinical judgment by the attending 
physician in the NICU. The open-label morphine analgesia was given to fewer neonates in the 
morphine group than in the placebo group, 202 (45.3%) vs. 242 (54.6%), p<0.006. 
 
Among the neonates who did not receive open-label morphine, the presence of severe IVH (9 vs. 3 
%, p=0.02) and composite outcome (24 vs. 15%, p=0.03) was more frequent in the morphine 
group. Again it was infants at 27 to 29 gestational weeks who were allocated to the morphine group 
who had a higher proportion of the composite outcome (20 vs. 9 %, p=0.03).  
 
Table 8. Factors associated with primary outcomes among neonates who did not receive additional 
analgesia, p-value, Modified from Anand, Bergqvist et al. Lancet 2004. 
OUTCOMES COMPOSITE DEATH SEVERE IVH PVL 
Treatment group 0.09 0.53 0.04 0.056 
Gestational age <0.001 <0.001 0.002 0.18 
CRIB score 0.02 0.00 - - 
Sex (M vs. F) 0.059 - - - 
Maternal antibiotics - 0.02 - - 
Maternal chorioamnionitis - - - 0.002 
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Number of painful and stressful procedures 
In the NEOPAIN trial, data were collected from 12 infants in Stockholm in whom all painful and 
potentially stressful procedures were registered, including all skin breaking procedures such as 
catheters (arterial, venous, umbilical cord and bladder), different punctures, intubation and 
procedures like x-rays and diaper changes etc. 
 
 
Figure 19.  Number of painful and stressful procedures during the first 8 weeks of life, in an infant 
born at 25 gestational weeks, who was included in the NEOPAIN study. Altogether 701 procedures 
were performed in this infant during 52 days of NICU stay, from Hébert-Wegmann, Bergqvist et al., 
unpublished data. 
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6.2 STUDY II – NEOPAIN TRIAL, PULMONARY OUTCOME 
The frequency of RDS and severity of illness (CRIB scores) was similar in the two groups 
(morphine and placebo). Infants in the morphine group needed mechanical ventilation on average 
one day (two days when early deaths were excluded) longer than infants in the placebo group. There 
were no significant differences of other respiratory variables between the two groups. 
 
To evaluate the effect of open-label morphine, data were analyzed in each group (morphine and 
placebo) by comparing infants who did versus did not receive open label morphine. Infants who 
received open label morphine (AA) had lower GA, BW, and Apgar scores at 1 and 5 minutes. These 
infants died more often and were also more ill with regards to CRIB score and the incidence of 
RDS, PDA, air leaks, chest tubes and BPD increased. Furthermore, the open label morphine group 
needed longer durations of mechanical ventilation, oxygen therapy and hospital treatment. 
 
To examine whether morphine therapy contributed to the respiratory outcomes outlined above, we 
adjusted for BW, CRIB scores (which include GA in the composite scores), maternal 
chorioamnionitis, RDS requiring surfactant, and PDA in our logistic regression models, using 
placebo/no label morphine as the reference group. Pre-emptive morphine infusions did not alter 
these outcomes, but the use of open label morphine (AA) continued to be a strong independent 
predictor of worse respiratory outcomes even after adjustment for the aforementioned factors, see 
table 9. 
 
Table 9, Effects of morphine open-label (AA) on respiratory outcomes, after adjustment for BW, 
CRIB scores, maternal chorioamnionitis, RDS requiring surfactant, and PDA, Modified from 
Bhandari, Bergqvist et al., Pediatrics 2005. 
 
OUTCOMES PLACEBO GROUP 
AA* 
MORPHINE GROUP 
AA* 
Air leaks, OR 3.43, p<0.01 4.28, p<0.01 
PPV, d NS 6.15, p<0.01 
PPV, d (excluding deaths) NS 6.67, p<0.01 
CV, d NS 3.17, p=0.06 
CV, d (excluding deaths) NS 3.66, p=0.04 
HFV, d 2.62, p<0.01 3.09, p<0.01 
HFV, d (excluding deaths) 2.62, p<0.01 3.09, p<0.01 
nCPAP, d 3.22, p=0.02 2.85, p=0.04 
Oxygen, d 7.16, p=0.01 8.12, p<0.01 
LOS NS 5.43, p=0.08 
BPD, OR NS NS 
BPD and/or death, OR NS NS 
   OR, odds ratio; NS, not significant (p>0.05); reference group placebo/no AA 
   Column Morphine/No AA was NS in all variables and not shown 
  * Placebo group/no AA was used as the reference group 
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6.3 STUDY III - CORTICAL ACTIVATION RESULTING FROM PAIN 
Heart rate and oxygen saturation 
Tactile stimulation did not change HR or SaO2. However, following pain, the mean (SD) HR 
increased significantly from baseline to 10 and 20 seconds after venipuncture, whereas the mean 
(SD) oxygenation saturation (%) decreased significantly during 10 to 40 seconds following 
venipuncture, see figures 20a and 20b. 
 
Figure 20a and 20b HR and oxygen saturation response to venipuncture, mean (SD), from Bartocci, 
Bergqvist et al., PAIN 2006.  
 
Cerebral oxygenation 
Tactile stimulation resulted in a small increase in [HbO2] concentrations in both cerebral 
hemispheres, which was further increased following painful stimulation. 
 
 
Figure 21. Response in cerebral oxygenation [HbO2] in the left and right hemispheres (left figure). 
Simultaneous recordings over the somatosensory and occipital cortex showed significant changes 
after tactile and pain stimulation, but only over the parietal area not over the occipital area, implying 
the functional specificity of this response, mean CI, from Bartocci, Bergqvist et al., PAIN 2006. 
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The response to pain was greater in the male than in female preterm neonates, see figure 22. 
 
Figure 22. Cortical response [HbO2] between the female (black columns) and male (white columns) 
neonates following venipuncture, males more pronounced, mean (SD), from Bartocci, Bergqvist et al., 
PAIN 2006.  
 
The [HbO2] increases after pain were positively correlated with postnatal age (r=0.75 left and r=0.67 
right hemisphere), and negatively correlated with the GA (r=−0.53 left and r=−0.42 right 
hemisphere. 
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6.4 STUDY IV – NEOPAIN, SEEING THROUGH THE BLIND! 
The ability of the professional neonatal staff to assess pain relive was tested in this study. We 
compared how the staff rated pain in mechanical ventilated preterm infants who received morphine 
or placebo in a double blinded design, with the same infants as in Paper I. 
 
Fifty two infants were assessed, 27 were randomized to the morphine group and 25 to the placebo 
group. There were no differences between the infants in these two groups, see table S2 in the 
publication. In total, physicians completed 99 forms, the nurses completed 179, and the assistant 
nurses 82 forms. The proportions of correct answers were 213 compared to 147, out of 360. Thus, 
59% of all answers correctly identified the assignment group (p<0.001). 
 
Table 10. The rates of correct answers were comparable between the groups of all neonatal staff, 
modified from Bergqvist et. al., Acta Paediatrica 2007.  
 
EDUCATION PERCENTAGE OF 
CORRECT ANSWERS
P-VALUE 
Physicians (N=62) 63%  
p=0.60 Nurses (N=107) 60% 
Assistant nurses (N=44) 54% 
NICU Experience  
<1 year (N=50) 62%  
p=0.28 1–5 years (N=64) 65% 
>5 years (N=99) 55% 
 
Increasing amounts of additional open label morphine before and during the study drug infusion 
reduced the staff's ability to correctly assess treatment group both before and during the study drug. 
  
Clinical factors 
Clinical factors that affected the staff´s ability to predict a correct answer: 
1. CRIB score had an Odds Ratio (OR) of 0.86 in predicting agreement with the Study Drug. 
Since “agreement” is the outcome being modelled, a baby with CRIB score 1 unit greater 
than the reference baby (with CRIB score=10), the probability of agreement with the Study 
Drug is reduced by 14% (0.86  vs. 1.0). In other words, the higher the CRIB score, the lower 
is the likelihood for “correct” identification of Study Drug.  This is clinically evident, since 
patients who are sicker will be less likely to show the clinical signs of pain vs. analgesia.  
Patients who are very sick hardly show any signs of pain, e.g., babies with NEC.  
2. Gender does not have a significant effect on correct identification of Study Drug(p=0.056, 
OR=0.58, CI=0.34–1.01), although there was a strong trend towards more frequent correct 
responses for male infants. This is consistent with the NIRS data, where male neonates 
showing greater cortical hemodynamic responses to acute pain as well.  
3. Other Factors: There were no effects on the ability of staff to assess the correct randomized 
group by other clinical factors Neonatal Medical Index (NMI), days on ventilatory support 
(CMV and HFOV), or plasma morphine levels. 
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6.5 STUDY V – MODE OF DELIVERY AFFECTS PAIN RESPONSIVNESS 
Heart rate 
The baseline HR was similar in both groups, VD and CS 135.5 (65.0) vs. 138.3 (50.8) bpm. The HR 
changes were larger after high intensity acute pain (vitamin K injection) as compared to the two 
low-intensity thermal stimuli (cold). The HR changes in response to high- and low-intensity stimuli 
were affected predominantly by the postnatal age (min) and the mode of delivery, see table 11. 
 
Table 11. Mode of delivery and postnatal age, modified from Bergqvist, et al. J Perinatol 2008. 
 
Dependent variable Independent variable p-value Explained variance (%)
HR%: pain PN age (min) 0.001 14.2 
 Mode of delivery 0.03 4.2 
HR%: cold PN age (min) 0.000 11.5 
  
HMS: pain Mode of delivery 0.000 36.6 
HMS: cold Mode of delivery 0.000 12.5 
  
Mean F0: pain Mode of delivery 0.04 7.3 
Mean F0: cold Mode of delivery 0.004 13.9 
  
Phonation time (%): pain Mode of delivery 0.002 21.6 
Phonation time (%): cold Mode of delivery NS  
 
During the first 4 h after birth, HR response to both stimuli increased progressively by postnatal age 
disregarding the mode of delivery (all infants). 
 
Following VD, the HR response to both high and low-intensity stimuli increased progressively by 
postnatal age whereas no such change was observed in the CS group, see figure 23. 
 
Figure 23. The HR response to high- and low-intensity stimuli with postnatal age in VD infants with 
a progressive increase of postnatal age (a), no such change was observed in CS infants (b). 
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Behavioural response 
The facial expressions were stronger during acute pain (vitamin K injection) as compared to the two 
thermal stimuli (cold). 
 
The facial expression, horizontal mouth stretch (HMS) was specifically affected by the mode of 
delivery whereas the other facial expressions were not. The HMS expression was less pronounced in 
VD than in CS infants in response to both higher and lower intensity stimuli. 
 
Figure 24. Mode of delivery affects the HMS facial expression to higher and lower intensity pain 
stimuli with a weaker response in the VD infants than CS infants with, modified from Bergqvist, et al. J 
Perinatol 2008 
 
Vocalization, acoustical and perceptual analysis 
It is remarkable that no vocalizations occurred in 10 of 53 VD infants and 1 of 23 CS infants 
following high-intensity painful stimuli (p=0.09, χ2-test), these infants could not be included in the 
analysis of vocalization. In the remaining infants, vocalizations were stronger during the vitamin K 
injection as compared to the two cold interventions. 
 
The high and low intensity stimuli were affected by the mode of delivery with mean F0 response, 
lower frequency band and longer vocalization latency in VD infants. 
 
 
Figure 25. Mode of delivery affects response time to high- and low-intensity pain stimuli with longer 
time to start of vocalization in VD infants than CS, modified from Bergqvist, et al. J Perinatol 2008 
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7 DISCUSSION 
 
7.1 FACTORS MODULATING NEONATAL PAIN RESPONSIVNESS 
The capability of the newborn infant to feel and remember pain has been underestimated for a very 
long time, leading to unnecessary painful experiences in this population. Infants and neonates are 
even more sensitive to pain due to the immaturity of endogenous modulation. Despite the newborn 
infants’ limited ability to communicate their pain, they should have the same human right to be 
alleviated from pain. 
 
A scientific rationale for this thesis are illustrated in the figure ??showing the pathophysiology by 
which the physiological and behavioural responses of neonates exposed to acute and repetitive 
painful stimuli may lead to development of IVH and PVL in the preterm infant. Why do some 
infants develop severe neurologic injury, whereas others with similar clinical characteristics appear to 
do well? Does repetitive pain play a role? Does hyperalgesia produced by acute pain contribute to 
this vulnerability? Can pre-emptive morphine prevent some of these complications?  
 
Figure 26 Pathophysiology of development to IVH and PVL, from Anand, Bergqvist, et al. Lancet 2004. 
 
In the NEOPAIN Multicenter Trial (Paper I-II, IV), pre-emptive morphine infusions did not 
reduce the frequency of neonatal death, severe IVH and PVL in mechanically ventilated preterm 
infants. In the subgroup 27 to 29 weeks of GA, the incidence of severe IVH was higher in the 
morphine group. Due to ethical reasons, the protocol was designed with intermittent extra bolus 
doses of morphine based on clinical judgement at each individual NICU. An increased incidence of 
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the composite primary outcome also occurred in those who received intermittent bolus doses of 
open-label morphine. 
Primary outcome in the two subgroups that did not receive any extra morphine doses showed an 
increase in the incidence of severe IVH and composite outcome (all infants), infants at GA 23 to 26 
weeks showed an increased incidence of severe IVH, and at GA 27 to 29 weeks showed an 
increased incidence of the composite outcome. Several other factors were related to primary 
outcome, as GA, CRIB score, maternal antibiotics and chorioamionitis, has been previously 
documented (Volpe 2001). The logistic regression analyses showed that none of the poor neurologic 
outcomes were related to the randomized treatment group (pre-emptive morphine analgesia), but in 
the subgroup analyses the incidence of severe IVH was correlated to treatment group. Hypotension 
occurred more frequently in the morphine group at the end of the loading dose and at 24 hours 
after start of the infusion drug. Reduced noradrenaline levels following morphine therapy in preterm 
neonates may explain this degree of hemodynamic instability (Quinn et al. 1992). Accumulation of 
the study drug in the group of 27 to 29 gestational weeks might occur, because of hepatic or renal 
dysfunction and the use of higher infusion rates (20 µg/kg/hr) in this group. 
 
The NOPAIN trial (Anand et al. 1999a) the pilot trial prior to the large NEOPAIN trial, that is 
included in this thesis. It showed that pre-emptive analgesia, may reduce the incidence of poor 
neurologic outcomes in preterm neonates who require mechanical ventilation support, but with a 
limitation in the sample size. 
 
The design was a loading dose of 100 µg/kg followed with 10, 20, or 30 µg/kg/hour for GA 23 
to 26, 27 to 29, and 30 to 32 weeks, respectively. Maybe this dose was too high? Simon et al 2003, 
had similar design with 150 neonates up to full term GA with the same loading dose but no 
increase in the infusion rate with GA, being standardized at 10 µg/kg/hour for all neonates. In 
this study, pre-emptive morphine analgesia actually decreased the incidence of IVH (23 vs. 40%, 
p=0.04) versus the placebo control group. 
 
The pre-emptive morphine infusions did not improve short-term pulmonary outcomes. Additional 
morphine aggravated respiratory outcomes in preterm neonates with RDS. Dyke et al reported that 
morphine therapy improved mechanical synchrony and reduced HR and respiratory rate, without 
altering blood pressure, but also decreased the duration of oxygen therapy (Dyke et al. 1995). A 
Cochrane  review by Bellu, 2008 concluded that there was no evidence for routine use of opioids in 
mechanical ventilated newborn infants (Bellu et al. 2008). We describe that pain expression during 
and after the loading dose decreases in the morphine group, with 1 PIPP score. Pain is central 
among the clinical outcomes that are selected for evaluation of opioid effects. 
 
Our conclusion is that continues infusions of morphine do not per se increase the vulnerability of 
ventilated preterm infants, in their risk for early neurological injury. Risk factors worsening 
neurologic outcomes may include: systemic hypotension before starting a morphine infusion, the 
need for repeated intravenous boluses, as well as increasing infusion rates in preterm neonates. The 
final recommendation with maximal effect and minimal side effect is an issue that still not is solved 
(Levene 2005). We still have the dilemma to balance the importance of relieving pain and side 
effects by giving analgesia. Our future plans to explore the opioid treatment with an individualized 
dosing strategy within the NeoOpioid Consortium that aims to improve analgesia in the newborn 
population is described further in this thesis. 
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7.2 GENDER ASPECTS IN NEONATAL PAIN 
Greater cortical activation was observed in male preterm neonates, in both cerebral hemispheres, 
contralateral and ipsilateral to the venipuncture, implying an increased neuronal activation caused by 
acute pain in the underlying brain regions (Paper III). This may result from surround-activation in 
the cortex and other areas activated to expand the signal, whereas other neonates (e.g. females) may 
develop surround-inhibition to localize the signal in these areas (Derdikman et al. 2003). 
Neurotransmitter release, use of metabolic energy, and activated or inhibited. Although neonatal 
NIRS response are modestly correlated with their pain assessments using PIPP scores, the greatest 
correlation occurs with facial expressions (Slater et al. 2008).  
 
In a previous study, gender differences occurred in pain expressions within preterm and term 
newborn infants, studied PN day 1 to 5, who required a capillary puncture. The pain scales NFCS 
and NIPS were evaluated at bedside prior, during, 1, 3, and 5 min after heel lancing. The NFCS 
score profile in female neonates of all gestational ages expressed more facial features of pain than 
male infants (p=0.025) (Guinsburg et al. 2000). It is possible that female neonates have greater facial 
expressiveness, whereas male neonates show greater physiological instability in response to pain. 
Our data strongly support the need for further studies, particularly because of the potential to 
explain long-term effects of neonatal pain 
 
Higher pain sensitivity occurred in ex-preterm girls in terms of tender points (Buskila et al. 2003), as 
compared to ex-preterm boys. We postulate that innate mechanisms of cell survival and cell 
differentiation in the developing preterm brains of boys and girls may be related to modelling of the 
pain system through adverse experiences in early life (Anand and Scalzo 2000b; Du et al. 2004). 
 
7.3 FREQUENCY OF CLINICAL PROCEDURES IN THE NICU 
The lack of central inhibition in the immature subject leads to exaggerated and generalized 
responses to all sensory inputs, affecting low as well as high-threshold stimuli. Specific pain 
responses may require convergent afferent inputs building up over time to become clinically 
apparent in the ex-preterm infants. 
 
In a nested study within the NEOPAIN trail, we calculated number of pain and stressful procedures 
during the NICU stay. It was surprising that a small neonate born at GA week 25, was exposed to 
700 procedures during 52 days NICU care. 
 
The nature and numbers of pain of invasive procedures is described by others, Baker at al describe 
over 3 000 procedures in 74% of the infants below 31 weeks in the NICU (Barker and Rutter 
1995b). More recently, Carbajal et al. found that each neonate experiences a median of 16 (range: 0-
62) procedures per day of NICU stay. Of these, 79.2% procedures are performed without specific 
analgesia. Greater prematurity, type of procedure, parental presence, surgery, and other factors were 
associated with greater use of procedural analgesia, whereas mechanical ventilation and nonspecific 
analgesia were associated with less use of procedural analgesia (Carbajal et al. 2008). It is evident that 
this degree of exposure to acute pain may be associated with long-term effects. 
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When evaluating 19 pain indicators including both physiology and behavioural parameters. There 
were no consistent differences in the factor structures when contextual factors were explored 
(Stevens et al. 2007).  
 
7.4 LONG-TERM EFFECTS OF UNTREATED PAIN 
Exposure to repetitive neonatal pain may cause permanent or long-term changes because of the 
developmental plasticity of the immature brain. In an animal study resembling NICU care, 
repeated daily pain stimuli; describe decreased pain thresholds during development (Anand et al. 
1999b). Increased plasticity of the neonatal brain may allow these and other changes in brain 
development to increase their vulnerability to stress disorders and anxiety-mediated adult 
behaviour (Anand and Scalzo 2000a; Bhutta et al. 2001). 
 
There are strong indications that chronic pain may affect the wiring of the neuronal networks 
possibly leading to attention deficit disorders (Bhutta and Anand 2002; Bhutta et al. 2002; Nagy et 
al. 2003). In the newborn infants, functional magnetic imaging (fMRI) was used to study the resting-
state networks driven by spontaneous signal fluctuations (Fransson et al. 2007). How does early pain 
affects these spontaneous activities with cerebral pain processing following NICU care? 
 
7.5 MODE OF DELIVERY 
Infants born after spontaneous VD showed a dampened behavioural (facial expression and 
vocalization) response to both pain and cold stimuli as compared to infants born by CS. 
Physiological responses (HR%) in VD infants were dampened just after birth, but increased 
progressively during the first hours after birth. This pattern was not evident among CS infants. 
 
The objective assessment of pain perception based on physiological criteria lacks specificity for 
newborn infant (Stevens and Franck 2001). An increase in HR is, however, one of the most 
frequently reported physiological sign of acute pain or stress. We monitored such increase in 
response to two types of stimuli, which affect the same nerves fibres (c- and Aδ-fibre) but with 
different intensity. Strong correlation between HR increases and tissue damage following 
circumcision, heel lance or immunization are well documented in infant, (Franck 1986; Stevens et al. 
1994; Johnston and Stevens 1996; Stevens et al. 2000) although no previous studies have examined 
these responses just after birth, or their progression in the hours following delivery, or the mode of 
delivery affects the strength of the response. 
 
The dampened behavioural and physiological responses to pain and cold stimuli in our VD infant 
population, especially within the initial hours after birth, suggest that newborn infants may remain in 
a state of foetal inhibition for a variable period of time immediately after birth. To further 
investigate this phenomenon, we randomized infants to receive pain and cold stimuli directly after 
birth (>30 to ≤90 min after delivery) or later (>90 to <120 min) in a more sleepy state. 
 
When fentanyl analgesia was administered to the foetus during invasive procedure at GA of 20 to 35 
week, an attenuated stress response to painful stimuli was found, indicating that the fetus can react 
to pain before birth (Fisk et al. 2001). 
 
Thus our findings suggest that VD per se triggers the activation of an analgesic mechanism. Very 
high levels of CA are released following VD (Faxelius et al. 1983; Lagercrantz and Slotkin 1986). 
The associated arousal is mediated by this sympathoadrenal activation is probably associated with 
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increased noradrenergic activation of the whole brain from the locus coeruleus (Lagercrantz 1996). 
Activation of adrenergic α2-receptor through the released noradrenaline may have strong analgesic 
effects like clonidine (Kamibayashi and Maze 2000). VD neonate also exhibits significantly higher 
plasma levels of β-endorphin than infant born by CS, which may further promote this difference 
(Facchinetti et al. 1986; Raisanen et al. 1986; Bacigalupo et al. 1987). The relative low baseline HR in 
the VD infants with gradual increase in HR after VD in response to pain and cold stimulus during 
the first 4 h after birth may also be due this endogen mechanism of stress-induced analgesia (Mogil 
et al. 1996). The rapid decline in circulating levels of β-endorphin during the initial 2 h following VD 
is in agreement with our findings. 
 
CS mothers in the present study received spinal anaesthesia with Bupivacaine, whereas VD mothers 
used N2O during uterine contractions in the first and second stage of labor. Bupivacaine given 
spinally remains inaccessible to the paravertebral venous plexus and is unlikely to cross the placenta 
to produce systemic effect in the foetus or neonate. Such effect of Bupivacaine would have resulted 
in a lower baseline HR in the CS than in VD infants, but no such difference actually occurred. As 
VD mother rapidly eliminate N2O through the lungs, it seems unlikely that N2O could affect their 
newborn infant studied at ≥30 min after delivery (Stenqvist 2000). 
 
7.6 CORTICAL ACTIVATION 
Neuronal activation within cortical areas is a network with regional changes in cerebral flow (r-
CBV), thus reflected in the [HbO2] changes measured in preterm newborn infants. Both tactile and 
painful stimuli elicited bilateral increases in cortical [HbO2] concentrations, implying increases in 
regional cerebral blood flow that resulted from changes in metabolic activity within the 
somatosensory cortical areas. Slater et al confirmed that similar cortical activation correlates with the 
behavioural responses to pain, with their overall PIPP score and particularly well with their facial 
expressions (Slater et al. 2008). However, some infants without any facial expressions and low PIPP 
scores were still noted to have cortical activation of the somatosensory areas. Further research to 
elucidate the neurophysiological correlates of these findings may explain the discrepancy between 
cortical activation responses and neonatal behavioural responses to acute pain.   
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8 CONCLUSIONS 
 
• We have demonstrated that pre-emptive morphine analgesia in very preterm infants does 
not reduce the primary neurological outcomes described as death, severe IVH or PVL. 
However, extra intermittent doses of morphine by clinical judgements were associated with 
an increased incidence of these outcomes. 
 
• Infants receiving the extra intermittent doses of morphine in the NEOPAIN trail had a 
lower gestational age, higher severity of illness score (CRIB), greater use of maternal 
antibiotics and more frequent signs of chorioamnionitis. Consequently, these sicker and 
smaller infants were at increased risk for early neurological injury already before opioid 
administration, which usually presents clinically as increased irritability. Greater irritability 
and agitation in ventilated preterm neonates may have been estimated as expression of pain 
and treated with morphine analgesia. 
 
• The pre-emptive morphine infusions did not improve short-term pulmonary outcomes, but 
additional morphine doses appeared to worsen the respiratory outcomes in preterm infants 
with RDS. Again, the caveat of greater severity of illness applies to these outcomes as well. 
 
• Prolonged pain in ventilated preterm neonates is extremely difficult to identify with any 
degree of accuracy. It is not surprising; therefore, that neither experience nor education 
improves the ability of professional NICU staff to estimate analgesia in preterm infants. 
Because of these difficulties in clinical assessments, we investigated other methods that may 
provide a clearer picture of pain responses in the immature brain. 
 
• Near infra-red spectroscopy documented a functionally specific somatosensory cortical 
activation following pain and tactile stimuli in preterm infants. We documented bilateral 
responses after a unilateral stimulus, and these responses were accentuated in male infants, 
at lower gestational ages, and at higher postnatal ages. A graded response in the 
somatosensory cortex supports the possibility of conscious sensory perception in preterm 
neonates. 
 
• Vaginally delivered term infants demonstrated less responsiveness to pain with facial 
expression, cry, and heart rate changes, following injection of vitamin K as compared with 
infants born by caesarean section. Pain and stress reactivity show dampened and gradually 
increasing pain response in the first hours following birth suggesting that there is a foetal 
inhibition activated during vaginal delivery, but this does not occur following caesarean 
section delivery. 
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Recommendation from our results 
 
o Reduce the numbers of painful or distressing procedures as much as possible in 
newborn infants. 
 
o Always assess newborn infants with validated pain assessment tools for all painful or 
stressful procedures. Additionally, use pain scales for estimation of chronic pain in 
all preterm and newborn infants needing intensive care treatment. 
 
o Register all pain and stressful interventions. 
 
o Continue further studies to investigate the safety and efficacy of other analgesics 
including opioid in ventilated neonates and develop more reliable methods to assess 
prolonged or chronic neonatal pain. 
 
o The challenge is to find the best ways to treat neonatal pain, with maximal analgesia 
and minimal side-effects from the short- and long-term perspective. 
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9 FUTURE DIRECTIONS 
My experience during these years have been educating in so many perspectives performing the 
practical recruitment for the patients in both NOPAIN and NEOPAIN studies. Have participated 
in meetings, discussions for design development to hypothesis, project plans, coordinated both 
National and International parts. 
 
Although our understanding of neonatal pain has increased during the last years, there are a 
number of remaining problems particularly with regard to alleviating drug treatment.  To develop 
consensus how to prevent and treat neonatal pain I have coordinated together with a team co-
workers in the design of an EU project to get a stream of all positive knowledge to improve our 
analgesia in the newborn infant. 
 
The overall aim of this EU project is to assess effects and safety of opioid treatment in very preterm 
infants in relation to pharmacokinetics and genetic predisposition. Furthermore, a major goal is to 
develop a Paediatric Use Marketing Authorisation (PUMA) for safe administration of opioid 
analgesic treatment in newborn infant. Both morphine and fentanyl are off-labelled (EMEA) drugs. 
Several studies have shown that opioid treatment in neonates reduce pain and stress responses. 
However, these drugs also have side-effects related to plasma concentrations of the drugs and their 
metabolites. The new approach in the current project is to obtain a more personalized drug therapy 
to the newborn infant, and to consider individual differences in pharmacokinetics and genetics, as 
well as gender effects. We will perform a multinational European survey of practices regarding 
sedation and analgesia in neonatal units. Clinical multicenter trial evaluating safety aspects of 
morphine and fentanyl will be performed. The responses (evaluated with validated pain scales, stress 
hormones, clinical variables, near infrared spectroscopy and aEEG) will be related to 
pharmacokinetics and genetic predisposition. There are strong indications that chronic pain may 
affect the wiring of the neuronal networks possibly leading to attention deficit disorders. In a few 
infants, functional magnetic imaging (fMRI) will be used to study cerebral pain processing, 
complementary to NIRS and aEEG measurements. A “child friendly” formulation adapted for use 
in neonates will be developed with by a SME partner in the project. The results will be disseminated 
by scientific and popular articles, the web, videos and special pain courses for physicians and nurses 
etc. The project will lead to a considerable improvement of the strategy to alleviate neonatal pain. It 
will also generate new information about brain development, pharmacokinetics and genetics. 
 
 
 
 
 
 
63 
 
10 ACKNOWLEDGEMENTS 
First of all, I would like to thanks all the children, parents and NICU staff that participated in the 
studies. This work would never have been possible without you. 
 
I would also like to thanks: 
 
My main supervisor, Professor Hugo Lagercrantz, for being an excellent scientist, creative, 
positive and full of energy, for having introduced me to the fascinating neonatal research in the 
newborn infant, for being patient, in good mood and with excellent capacity to bring things to a 
conclusion. You have made me appreciate research, especially at times when I that found it difficult. 
I do admire your wide knowledge within so many areas, with the main focus on the newborn infant. 
 
My co-supervisor, Professor K.J.S. “Sunny” Anand “The Neonatal Pain Guru”, for introducing 
me in the field of pain research, educated and follow me during the whole PhD time, supported my 
participation in the NOPAIN and NEOPAIN trials, the best proof-reader. Your wisdom is so deep, 
that combines science, with the different cultures in US and India. Thank you for taking care of me 
during my visits to US. It has also been a great privilege to learn to know your family, lovely wife Iti, 
and your charming children Amrit and Tej. 
 
My co-supervisor, Associate Professor Miriam Katz-Salamon, for being creative, full of energy 
to analyse data, be supportive and an excellent poster designer. Thank you for all practical and 
theoretical discussions. 
 
My co-supervisor, Associate Professor Lena Hellström-Westas, for your enthusiasm to put this 
thesis book together, and for giving positive feedback on the performed trials. I admire your 
“guidelines”, and I hope that we can continue our discussions about the complexity of being a 
female doctor, scientist and mother. Supportive 
 
My former co-supervisor, Associate Professor Josef Milerad, for your enthusiasm and time as a 
new researcher, introduced me in the practical research before Läkartidningen took all your time. 
 
Karolinska Institutet, for let me performing this thesis under your guidelines. Department of 
Woman and Child Health, head of the department Olle Söder, for support and I remember the 
time at the NICU when I recruited the NEOPAIN patients under your guidelines. Head of 
administrative Thomas Walstam thanks for all your support it has been a pleasure to work with 
you, looking forward to our NeoOpioid Consortium. Administrative support Astrid Häggblad for 
always being there, to guide me in the academically world. Other co-workers contributed to this 
thesis None-Marie Kemp, Britt Masironi for your support, Ann-Christin Eklöv, Fredrik Ullén, 
Head of Grant Office, Miles Davies, for your support and engagement with our FP7 project. Eva 
Björndal, for all your support understanding the budget, and the legal support from Malin Wallin 
and Viktoria Söderqvist,  Other co-workers at the KBH Susanne Hallberg LIME with 
Elisabeth Berg, Jakob Bergström, Ulf Brodin and Margareta Krook-Brandt. 
 
 64 
 
Neonatal Research Unit, Eva Lundberg, for your support and guidance in administration and 
economical issues. Ruth Detlofsson, for being so kind listening neighbour in the brainstorm room. 
Former lab collaborators Ingrid Dahlin, for your guide and many remember full times at the “old” 
lab. Viveca ID Karlsson for your administrative support. All in former and present co-workers and 
friend in the Brain storm room, Julie Peyronnet and Jean-Christoph Roux, Zachi Horn, Jonas 
Berner and Max Winerdahl my supportive room friends, Malin Rohdin, Yuri Shvarev, Ulrika 
Åden, Beatrice Skiöld, Ronny Wickström, Erik Herlenius, Thomas Ringstedt, for share your 
travel experience,  Linus Olsson for all your IT support, Jeongsook Park, Jakob Karlsson, Lena 
Swartling, Zoltan Nagy, Linda-Maria Jäderstad, Johan Jäderstad, Marco Bartocci, Anna 
Gunnerbeck, Hans Holgert, Zachi Horn, Anna Hårdemark, Yinghua Li, Liequi, Annika 
Olsson, Panos Papachristou, Maria Lindqvist, and all others that I meet during these years. 
  
Astrid Lindgren – Karolinska hospital, for allow me make the clinical trials within the 
organisation. Thanks Eva Horemuzova, for being the best listening friend and colleague in my life. 
Neonatal unit, thanks to all that was being supportive at the unit performing these trials. The head 
of the department  Eva Berggren-Broström, Baldvin Jónsson, Susanne Abenius, , specially the 
nurses Elinor Ihré, Agneta Green, Veronica Berggren, Ann-Sofie Gustavsson, nurses. Mikael 
Norman thanks for being a supportive listener, , Stefan Johansson very kind supportive 
neonatologist, Gerd Faxelius, a woman that I admire, Björn Westrup, Giovanna Marchini, head 
of the Pain unit Stefan Lundberg, Leena Jylli and your pain support team. Björn A Larsson, for 
introducing me in pain research, Tord Andersson, Camilla Dahlskog and Sara Grönberg for 
their help with part of the NFCS scoring. Carin Allert the wonderful physiotherapist traveling to 
perform the NEOPAIN follow-up, you learned me so much. Britt-Marie Anderlid, Fredrika 
Gauffin for all your work and support, Ann Edner, Lena Legnevall, Carina for our nice time 
together and Keth Lothian, Björn Lundberg, Bo Magnusson, looking forward to the ALB 
collaboration Helena Martin, Mikael Moskin, Felicia Grunewald-Nordenstam, P-A Rydelius, 
Ulrika Walfridsson, Mireille Vanpee, Hans Wessel, Elisabeth Wolf, Staffan Arnér, Mats 
Blennow, The-Hung Bui, Birgitta Böhm, Bea Duse, Ann Edner, Birgit Garmelius 
supportive pharmacist within the NEOPAIN, Bo and Anders Nordell, and Märta Segerdahl, All 
midwives at the delivery ward Britt Gustavsson, Annika Denbaum and Annika Gustavsson m 
Birgitta Böhm, Boubou Hallberg and Andreas Henschen for our discussions and special 
thanks for taking care of our Ida when she was born, thanks all and also all names that not are 
printed here but been supportive. 
 
Jämtlands Läns Landsting, with Östersunds Hospital, together with Järpen and Åre 
Hälsocentraler. Special thanks to the head at the paediatric department Urban Tirén, my clinical 
supervisor Mattias Kjellberg for your good support and expressions, Inge Axelsson always 
interested to educate and share your experience, Kari Arhimaa, you know so much, Ragnar 
Asplund, Ingrid Bergner, Flemming Mörk-Petersen, Anna-Lena Fureman, Catrin Holgén, 
Johanna Lindqvist, Estelle Naumburg, Per, Lotta, and all others at BUM, Thomas Adler, Alf 
Lerner, Christina Reuterwal, Susanne Johansson, Christina Lithner, Emma Lycksell, Erik 
Malers, Annika Nyström, Monica Olausson, Mattias Schindele, Jakob Swanberg, Gustav 
Trehn, Louise Vejdeland, Jessica Westman, Arne Wickström, Christine Woxlägd, Sofia Leije 
and all others that I meet during my years at JLL. 
 
 
 
 
 
 
65 
 
Örebro University Hospital, Jens Schollin, my former head and college Mats Eriksson also my 
former head of when I started my carrier as a nurse, thanks for be a trustable collaborator. Maria 
Gradin, Yvonne Skogsberg , Elisabeth Esbjörner, Siv Karlsson, and all others in Örebro a very 
nice clinic for children that take good care of the children. 
 
Other co-workers and friend around the world doctor Pia Baumann, for all time together the 
delivery word hunting umbilical cords, a very good friend and mother to my god sun Adam 
together with Fanny, Klara, Andrea, and husband Christian Thanks for letting know your lovely 
family. Tina Berglin-Crafoord, JORAB with BIOPAC and AcqKnowledge software Björn Palm 
and Fredrik Rådesand for discussions and technical support. Stellan Hertegård, for introduce 
and given my support in the phonation research. Eva Björkner, Karin Nyberg and Agneta 
Österman, Eva Björkner, for your co-working in the phonation research. Speech therapists Maria 
Södersten, Eva Borell and Elisabet Lundström as listeners of vocalizations to the perceptual 
estimation in supervision of Tord Andersson, Camilla Dahlskog and Sara Grönberg, Lars 
Björklund, Marie-Louise Borg, Lena Antin, Allen Finley, Ulrika Forss, Mirtha Grande-
Cederberg, Jean-Pierre Guignard, Nicole Hebert-Wegmann, Kerstin Hertzman, Helmut 
Hummler, Cathrine Dolk, Celeste Johnston, Karl-Patrik Jonsson, Hanna Kapadia, Anna 
Leifler, Magnus Lindgren, Maja Lundqvist, Joachim Luthander, Michael Borgert, Johan 
Monsén, Emelie Nordenhök, Ragnar Olegård, Anna-Karin Olofsson, Predrag Petrovic, 
Johanna Rubin, Göran Sjönell, Jan Stepniewski, Bonnie Stevens, Karin Stjernqvist, Anna 
Söderholm, Karin Wahlberg, Mikael Wester, Magnus Westgren, Zsuzsanna Wiesebfeld-
Hallin, Birgitta Wikander, and Birger Winbladh thanks all others during this year’s. 
Thanks to Per Hansson, Maria Fitzgerald, Kenneth D Craigh and Ruth VE Grunau and my 
supervisors for re-publishing your figures.   
The NEOPAIN team thanks to all you has given me so much in science, culture and friends. In 
US, Maryland Medical Research Institute, Baltimore, Bruce A Barton the chief statisticians, Shari S 
Kronsberg, for all your statistical support and Sharon Fick, for all your administrative support. 
Arkansas Children's Hospital, Little Rock Richard Whit Hall for our discussions and laugh, T J 
Green, Cynthia R. Rovnaghi, Kris Dudoich for your administrative support, University of 
Kentucky, Lexington, Nirmala Desai and Vicki L Whitehead. New England Floating Hospital 
Barbera A Shephard and Brend Mac-Kinnon for given me the US NICU perspective, Wake 
Medical Center, Raleigh, Tom E Young for all our discussion and let me know your lovely wife, 
Kimberly Carr. Medical Center, Chicago Rohitkumar B Vasa, University of Pennsylvania, 
Philadelphia Vinny K Bhutani. Medical Center of Delaware and University of Illinois, Chicago, 
Delaware Deborah, R Bhat, Albert Einstein Medical Center, Philadelphia, Vineet K Bhandari 
for our discussions and manuscript writing. Rama Bhat, Josephine Brown for learning me so 
much about newborn infants behavior. In Europe, France, Centre Hospitalier Poissy Saint 
Germain, Ricardo Carbajal, Richard Lenclen. UK, Simpson Memorial Maternity Pavilion, 
Edinburgh Neil Mclntosh, Gopi Menon, and Elaine M Boyle. 
The NeoOpioid Consortium our project office Fergal Donnelly, Maria Psimenopoulou, and 
EMEA Agnes Saint Raymond for carrying about the newborn medical treatment, Anders Rané 
thanks for your support and friendship. Sture Andersson, Angela Noble, John Van Den Anker, 
Uwe Ewald, Vineta Fellman, Anne-Marie Illsley, Matthias Keller, Elisabeth Norman, Jean-
 66 
 
Pierre Osselaere, Jeroen Peters, Ron van Schaik, Anne Soetemont, Dick Tibboel, and Bart 
Van Overmeire and all others part of the Consortium. 
 
The Swedish NCP at VINNOVA for your knowledge and support Gunnar Sandberg. 
 
FUNDING 
This thesis were supported by several funding, Thanks to National Institute of Health (NIH, HD 
36484 and HD36270), Swedish Science Foundation, Swedish Medical Association, The Vårdal 
Foundation, Medical Association at Karolinska Institute, The Wallenberg Foundation, Sällskapet 
Barnvård Foundation, Samariten Foundation, Karolinska Institutet funding, Hennerlöfska 
funding SLS, KI travel funds, SVLS, Folke Bernadotte Stiftelse, Föreningen Mjölkdroppen, 
Freemason Society in Stockholm, KI department of Woman and Child Health, the Medical 
Research Council grant nr 5234, Allmänna BB´s minnesfond, Stockholms läkareförening, Sven 
Jerring Foundation Kempe-Calgrenska Foundation, First of May Flower Foundation, 
Gothenburg, and The Research and Development Unit, Jämtland County Council, Östersund, 
and Torsten Nand Ragnar Söderberg foundation. 
 
Family and friends 
My other half and husband Göran for all your support, remembering the important in lift, my lovely 
and inspirited daughter Ida. My lovely parents that always standing by me and my families’ side 
Arne and Ulla-Britt Bergqvist. My cousins with families Jim and Tord du Rietz, Ann 
Söderström with children. My husband’s Rudolf Hägglund 106 years old grandfather, you give 
me a lovely perspective of life. Sonja Larsson my husband’s mother I admirer your strength, and 
Pelle, Håkan Larsson, my husband’s big brother for correcting the language and supportive 
discussions with family Lena Grönlund and children Gunnar and Maria. Hans, Kristina, Gustav 
and Axel. 
 
Karin Larsson one of my oldest friend, that lives to fare away in Australia. Yvonne Lindberg for a 
very good friend that can listen and your Ingvar. Iris Frödin my extra grandmother. Inger and 
Johan Printz-Ahlstedt and Agnes, Peter and Eva Andersson, Mette Aspen-Ahlsson,Otti 
Bergendahl, Svetlana Lagercrantz, Caarina Bergh, Bartoz and Maja Wykrzykowski, Jennifer, 
Idas godmother, Sergey, Emily, Pytro for inviting us to your lovely paradise in Italy and Kurzin, 
Tahir Baratov with family, Anna and Lasse Borg, Minna Borgström, Daniela and Georg 
Brugger, Gittan Codan, Ulf Draggart and Katrin Persson, Agneta Eiserborn, Tina Eklund, 
Roger Larsson and Kalle Eriksson with Julia. Kajsa and Magnus Erlingmark, Maria 
Ernfridsson-Grehn, Alex and Danuta Faron, Håkan Fernström, Mikael Fiedler, Iris Frödin, 
Paul and Steffi Gruner, Berth Haglund, Per-Arne Hedvall, Helen and Robert Hallkvist, 
Gisela Hellgren, and Miko, Peter and Marie Herlitz, Kerstin Hesselgren, Bo Holm, Brittas-
Lennart Eriksson, Kjerstin Hyggen, Erika Hörnfeldth, John and Eva Jouper, Rickard 
Olsson, Lena Larsson and Asta, Krister and Lena Lundin, Maivor Sånnevall, The whole 
family Majda, Maj Ny, Anders and Pernilla Nyberg, Anders and Susanne Olofsson, Herbert 
and Renate Opitz, Johan and Birgitta Palmgren, Jan Perrin, Margareta Persson, Karin 
Rognehag, Annelie and Niclas Sjöberg, Erika, Göran, Ofelia and Emmy Wallmo, Åsa 
Spånberg, Maria Steinert, Anders Warensjö, Maria Helena Wickenberg and all other friends 
during these. 
 
 
 
 
67 
 
11 REFERENCES 
Als H, Brazelton TB. A new model of assessing the behavioral organization in preterm and 
fullterm infants: two case studies. J Am Acad Child Psychiatry 1981;20(2):239-263. 
Als H, Gilkerson L. The role of relationship-based developmentally supportive newborn 
intensive care in strengthening outcome of preterm infants. Semin Perinatol 
1997;21(3):178-189. 
Ambuel B, Hamlett KW, Marx CM, Blumer JL. Assessing distress in pediatric intensive care 
environments: the COMFORT scale. J Pediatr Psychol 1992;17(1):95-109. 
Anand KJ. Pain, plasticity, and premature birth: a prescription for permanent suffering? Nat Med 
2000a;6(9):971-973. 
Anand KJ. Anesthetic neurotoxicity in newborns: should we change clinical practice? 
Anesthesiology 2007;107(1):2-4. 
Anand KJ, Aynsley-Green A. Measuring the severity of surgical stress in newborn infants. J 
Pediatr Surg 1988;23(4):297-305. 
Anand KJ, Barton BA, McIntosh N, Lagercrantz H, Pelausa E, Young TE, Vasa R. Analgesia 
and sedation in preterm neonates who require ventilatory support: results from the 
NOPAIN trial. Neonatal Outcome and Prolonged Analgesia in Neonates. Arch Pediatr 
Adolesc Med 1999a;153(4):331-338. 
Anand KJ, Coskun V, Thrivikraman KV, Nemeroff CB, Plotsky PM. Long-term behavioral 
effects of repetitive pain in neonatal rat pups. Physiol Behav 1999b;66(4):627-637. 
Anand KJ, Garg S, Rovnaghi CR, Narsinghani U, Bhutta AT, Hall RW. Ketamine reduces the 
cell death following inflammatory pain in newborn rat brain. Pediatr Res 
2007;62(3):283-290. 
Anand KJ, Hall RW. Pharmacological therapy for analgesia and sedation in the newborn. Arch 
Dis Child Fetal Neonatal Ed 2006;91(6):F448-453. 
Anand KJ, Hall RW, Desai N, Shephard B, Bergqvist LL, Young TE, Boyle EM, Carbajal R, 
Bhutani VK, Moore MB, Kronsberg SS, Barton BA. Effects of morphine analgesia in 
ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial. 
Lancet 2004;363(9422):1673-1682. 
Anand KJ, Hansen DD, Hickey PR. Hormonal-metabolic stress responses in neonates 
undergoing cardiac surgery. Anesthesiology 1990;73(4):661-670. 
Anand KJ, Maze M. Fetuses, fentanyl, and the stress response: signals from the beginnings of 
pain? Anesthesiology 2001;95(4):823-825. 
Anand KJ, Scalzo FM. Can adverse neonatal experiences alter brain development and 
subsequent behavior? Biol Neonate 2000a;77(2):69-82. 
Anand KJS. Pain, plasticity, and premature birth: a prescription for permanent suffering? Nat 
Med 2000b;6(9):971-973. 
Anand KJS, Coskun V, Thrivikraman KV, Nemeroff CB, Plotsky PM. Long-term behavioral 
effects of repetitive pain in neonatal rat pups. Physiol Behav 1999c;66(4):627-637. 
Anand KJS, Craig KD. New perspectives on the definition of pain. Pain 1996;67(1):3-6; 
discussion 209-211. 
Anand KJS, Hickey PR. Pain and its effects in the human neonate and fetus. N Engl J Med 
1987;317(21):1321-1329. 
Anand KJS, Scalzo FM. Can adverse neonatal experiences alter brain development and 
subsequent behavior? Biology of the Neonate 2000b;77((2)):69-82. 
Anand KJS, Sippell WG, Aynsley-Green A. Pain, anaesthesia, and babies. Lancet 
1987;2(8569):1210. 
Anderson BJ, Palmer GM. Recent pharmacological advances in paediatric analgesics. Biomed 
Pharmacother 2006;60(7):303-309. 
Andrews K, Fitzgerald M. The cutaneous withdrawal reflex in human neonates: sensitization, 
receptive fields, and the effects of contralateral stimulation. Pain 1994;56(1):95-101. 
Apgar V. A proposal for a new method of evaluation of the newborn infant. Curr Res Anesth 
Analg 1953;32(4):260-267. 
Apgar V, Kreiselmen J. Studies on resuscitation; an experimental evaluation of the Bloxsom air 
lock. Am J Obstet Gynecol 1953;65(1):45-52. 
 68 
 
Arthur GC. Somatic sensations: II Pain, headache, and therminal sensations. In: GC Arthur, 
editor Book Title|, Vol. Volume|. City|: Publisher|, Year|. p.^pp. Pages|. 
Asprey JR. Postoperative analgesic prescription and administration in a pediatric population. J 
Pediatr Nurs 1994;9(3):150-157. 
Bacigalupo G, Langner K, Schmidt S, Saling E. Plasma immunoreactive beta-endorphin, ACTH 
and cortisol concentrations in mothers and their neonates immediately after delivery--
their relationship to the duration of labor. J Perinat Med 1987;15(1):45-52. 
Barker D, Rutter N. Analgesic effect of sucrose. Heel pricks were unnecessarily painful. Bmj 
1995a;311(7007):747. 
Barker DP, Rutter N. Exposure to invasive procedures in neonatal intensive care unit 
admissions. Arch Dis Child Fetal Neonatal Ed 1995b;72(1):F47-48. 
Barr RG. Herbal teas for infantile colic. J Pediatr 1993;123(4):669; author reply 670-661. 
Barr RG, Rappaport L. Infant colic and childhood recurrent abdominal pain syndromes: is there 
a relationship? J Dev Behav Pediatr 1999;20(5):315-317. 
Barrett DA, Barker DP, Rutter N, Pawula M, Shaw PN. Morphine, morphine-6-glucuronide and 
morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine 
infusions. Br J Clin Pharmacol 1996;41(6):531-537. 
Bellu R, de Waal KA, Zanini R. Opioids for neonates receiving mechanical ventilation. 
Cochrane Database Syst Rev 2005(1):CD004212. 
Bellu R, de Waal KA, Zanini R. Opioids for neonates receiving mechanical ventilation. 
Cochrane Database Syst Rev 2008(1):CD004212. 
Benini F, Johnston CC, Faucher D, Aranda JV. Topical anesthesia during circumcision in 
newborn infants. Jama 1993;270(7):850-853. 
Beyer JE, McGrath PJ, Berde CB. Discordance between self-report and behavioral pain 
measures in children aged 3-7 years after surgery. J Pain Symptom Manage 
1990;5(6):350-356. 
Bhat R, Abu-Harb M, Chari G, Gulati A. Morphine metabolism in acutely ill preterm newborn 
infants. J Pediatr 1992;120(5):795-799. 
Bhutta AT, Anand KJ. Vulnerability of the developing brain. Neuronal mechanisms. Clin 
Perinatol 2002;29(3):357-372. 
Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand KJ. Cognitive and behavioral 
outcomes of school-aged children who were born preterm: a meta-analysis. Jama 
2002;288(6):728-737. 
Bhutta AT, Rovnaghi C, Simpson PM, Gossett JM, Scalzo FM, Anand KJ. Interactions of 
inflammatory pain and morphine in infant rats: long-term behavioral effects. Physiol 
Behav 2001;73(1-2):51-58. 
Bhutta AT, Venkatesan AK, Rovnaghi CR, Anand KJ. Anaesthetic neurotoxicity in rodents: is 
the ketamine controversy real? Acta Paediatr 2007;96(11):1554-1556. 
Blass E, Fitzgerald E, Kehoe P. Interactions between sucrose, pain and isolation distress. 
Pharmacol Biochem Behav 1987;26(3):483-489. 
Blauer T, Gerstmann D. A simultaneous comparison of three neonatal pain scales during 
common NICU procedures. Clin J Pain 1998;14(1):39-47. 
Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of 
morphine and its metabolites in neonates, infants and young children. Br J Anaesth 
2004;92(2):208-217. 
Boyle EM, Freer Y, Khan-Orakzai Z, Watkinson M, Wright E, Ainsworth JR, McIntosh N. 
Sucrose and non-nutritive sucking for the relief of pain in screening for retinopathy of 
prematurity: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 
2006a;91(3):F166-168. 
Boyle EM, Freer Y, Wong CM, McIntosh N, Anand KJS. Assessment of persistent pain or 
distress and adequacy of analgesia in preterm ventilated infants. Pain 2006b;124(1-2):87-
91. 
Brazelton TB. The Brazelton Neonatal Behavior Assessment Scale: introduction. Monogr Soc 
Res Child Dev 1978;43(5-6):1-13. 
Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad 
Sci U S A 1993;90(12):5391-5393. 
Burns JP. Research in children. Crit Care Med 2003;31(3 Suppl):S131-136. 
Buskila D, Neumann L, Zmora E, Feldman M, Bolotin A, Press J. Pain sensitivity in 
prematurely born adolescents. Arch Pediatr Adolesc Med 2003;157(11):1079-1082. 
 
 
 
69 
 
Campos Banales ME, Perez Pinero B, Rivero J, Ruiz Casal E, Lopez Aguado D. Histological 
structure of the vocal fold in the human larynx. Acta Otolaryngol 1995;115(5):701-704. 
Carbajal R, Lenclen R, Jugie M, Paupe A, Barton BA, Anand KJ. Morphine does not provide 
adequate analgesia for acute procedural pain among preterm neonates. Pediatrics 
2005;115(6):1494-1500. 
Carbajal R, Rousset A, Danan C, Coquery S, Nolent P, Ducrocq S, Saizou C, Lapillonne A, 
Granier M, Durand P, Lenclen R, Coursol A, Hubert P, de Saint Blanquat L, Boelle PY, 
Annequin D, Cimerman P, Anand KJ, Breart G. Epidemiology and treatment of painful 
procedures in neonates in intensive care units. JAMA 2008;300(1):60-70. 
Chadwick J. Hippocrates of Cos. Guys Hosp Rep 1951;100(3):210-222. 
Craig A. A new view of pain as a homeostatic emotion. Trends in Neurosciences, 
2003;26(6):303-307. 
Craig KD, McMahon RJ, Morison JD, Zaskow C. Developmental changes in infant pain 
expression during immunization injections. Soc Sci Med 1984;19(12):1331-1337. 
Craig KD, Whitfield MF, Grunau RV, Linton J, Hadjistavropoulos HD. Pain in the preterm 
neonate: behavioural and physiological indices. Pain 1993;52(3):287-299. 
Darwin C. The expression of the emotions in Man and Animals. London: John Murray, 1872. 
Debillon T, Zupan V, Ravault N, Magny JF, Dehan M. Development and initial validation of the 
EDIN scale, a new tool for assessing prolonged pain in preterm infants. Arch Dis Child 
Fetal Neonatal Ed 2001;85(1):F36-41. 
Derdikman D, Hildesheim R, Ahissar E, Arieli A, Grinvald A. Imaging spatiotemporal 
dynamics of surround inhibition in the barrels somatosensory cortex. J Neurosci 
2003;23(8):3100-3105. 
Du L, Bayir H, Lai Y, Zhang X, Kochanek PM, Watkins SC, Graham SH, Clark RS. Innate 
gender-based proclivity in response to cytotoxicity and programmed cell death pathway. 
J Biol Chem 2004;279(37):38563-38570. 
Dyke MP, Kohan R, Evans S. Morphine increases synchronous ventilation in preterm infants. J 
Paediatr Child Health 1995;31(3):176-179. 
Eriksson J, Jablonski A, Persson AK, Hao JX, Kouya PF, Wiesenfeld-Hallin Z, Xu XJ, Fried K. 
Behavioral changes and trigeminal ganglion sodium channel regulation in an orofacial 
neuropathic pain model. Pain 2005;119(1-3):82-94. 
Eriksson M, Finnström O. Can daily repeated doses of orally administered glucose induce 
tolerance when given for neonatal pain relief? Acta Paediatr 2004;93(2):246-249. 
Eriksson M, Gradin M, Schollin J. Oral glucose and venepuncture reduce blood sampling pain in 
newborns. Early Hum Dev 1999a;55(3):211-218. 
Eriksson M, Gradin M, Schollin J. Oral glucose and venepuncture reduce blood sampling pain in 
newborns. Early Hum Dev 1999b;55(3):211-218. 
Evans DJ, MacGregor RJ, Dean HG, Levene MI. Neonatal catecholamine levels and 
neurodevelopmental outcome: a cohort study. Arch Dis Child Fetal Neonatal Ed 
2001;84(1):F49-52. 
Facchinetti F, Bagnoli F, Sardelli S, Petraglia F, De Leo V, Bracci R, Genazzani AR. Plasma 
opioids in the newborn in relation to the mode of delivery. Gynecol Obstet Invest 
1986;21(1):6-11. 
Faxelius G, Hagnevik K, Lagercrantz H, Lundell B, Irestedt L. Catecholamine surge and lung 
function after delivery. Arch Dis Child 1983;58(4):262-266. 
Finnström O. Neurosensory outcome and growth at three years in extremely low birthweight 
infants: follow-up results from the Swedish national prospective study. Acta Paediatr 
1998;87(10):1055-1060. 
Finnström O, Otterblad Olausson P, Sedin G, Serenius F, Svenningsen N, Thiringer K, Tunell R, 
Wesstrom G. Neurosensory outcome and growth at three years in extremely low 
birthweight infants: follow-up results from the Swedish national prospective study. Acta 
Paediatr 1998;87(10):1055-1060. 
Finnström O, Schollin J. [Newborn infants do feel pain! Technique and environment in 
connection with specimen collection can be improved]. Lakartidningen 
1998;95(50):5718-5720. 
 70 
 
Fisk NM, Gitau R, Teixeira JM, Giannakoulopoulos X, Cameron AD, Glover VA. Effect of 
direct fetal opioid analgesia on fetal hormonal and hemodynamic stress response to 
intrauterine needling. Anesthesiology 2001;95(4):828-835. 
Fitzgerald M. The development of activity evoked by fine diameter cutaneous fibres in the 
spinal cord of the newborn rat. Neurosci Lett 1988;86(2):161-166. 
Fitzgerald M. The development of nociceptive circuits. Nat Rev Neurosci 2005;6(7):507-520. 
Fitzgerald M, Koltzenburg M. The functional development of descending inhibitory pathways in 
the dorsolateral funiculus of the newborn rat spinal cord. Brain Res 1986;389(1-2):261-
270. 
Fitzgerald M, Millard C, McIntosh N. Cutaneous hypersensitivity following peripheral tissue 
damage in newborn infants and its reversal with topical anaesthesia. Pain 1989;39(1):31-
36. 
Fitzgerald M, Shaw A, MacIntosh N. Postnatal development of the cutaneous flexor reflex: 
comparative study of preterm infants and newborn rat pups. Dev Med Child Neurol 
1988;30(4):520-526. 
Franck L. A new method to quantitatively describe pain behavior in infants. Nurs Res 
1986;35:28-31. 
Franck LS, Boyce WT, Gregory GA, Jemerin J, Levine J, Miaskowski C. Plasma 
norepinephrine levels, vagal tone index, and flexor reflex threshold in premature 
neonates receiving intravenous morphine during the postoperative period: a pilot study. 
Clin J Pain 2000;16(2):95-104. 
Fransson P, Skiold B, Horsch S, Nordell A, Blennow M, Lagercrantz H, Aden U. Resting-state 
networks in the infant brain. Proc Natl Acad Sci U S A 2007;104(39):15531-15536. 
Fried K, Bongenhielm U, Boissonade FM, Robinson PP. Nerve injury-induced pain in the 
trigeminal system. Neuroscientist 2001;7(2):155-165. 
Friedrichs JB, Young S, Gallagher D, Keller C, Kimura RE. Where does it hurt? An 
interdisciplinary approach to improving the quality of pain assessment and management 
in the neonatal intensive care unit. Nurs Clin North Am 1995;30(1):143-159. 
Gaston-Johansson F, Asklund-Gustafsson M. A baseline study for the development of an 
instrument for the assessment of pain. J Adv Nurs 1985;10(6):539-546. 
Giannakoulopoulos X, Sepulveda W, Kourtis P, Glover V, Fisk NM. Fetal plasma cortisol and 
beta-endorphin response to intrauterine needling. Lancet 1994;344(8915):77-81. 
Gradin M, Eriksson M, Holmqvist G, Holstein A, Schollin J. Pain reduction at venipuncture in 
newborns: oral glucose compared with local anesthetic cream. Pediatrics 
2002;110(6):1053-1057. 
Gradin M, Finnström O, Schollin J. Feeding and oral glucose--additive effects on pain reduction 
in newborns. Early Hum Dev 2004;77(1-2):57-65. 
Granqvist S, Hammarberg B. The correlogram: a visual display of periodicity. J Acoust Soc Am 
2003;114(5):2934-2945. 
Grunau RE, Holsti L, Whitfield MF, Ling E. Are twitches, startles, and body movements pain 
indicators in extremely low birth weight infants? Clin J Pain 2000;16(1):37-45. 
Grunau RE, Oberlander TF, Whitfield MF, Fitzgerald C, Lee SK. Demographic and therapeutic 
determinants of pain reactivity in very low birth weight neonates at 32 weeks' 
postconceptional Age. Pediatrics 2001;107(1):105-112. 
Grunau RV, Craig KD. Pain expression in neonates: facial action and cry. Pain 1987;28(3):395-
410. 
Grunau RV, Johnston CC, Craig KD. Neonatal facial and cry responses to invasive and non-
invasive procedures. Pain 1990;42(3):295-305. 
Guinsburg R, de Araujo Peres C, Branco de Almeida MF, de Cassia Xavier Balda R, Cassia 
Berenguel R, Tonelotto J, Kopelman BI. Differences in pain expression between male 
and female newborn infants. Pain 2000;85(1-2):127-133. 
Hall RW, Kronsberg SS, Barton BA, Kaiser JR, Anand KJ. Morphine, hypotension, and adverse 
outcomes among preterm neonates: who's to blame? Secondary results from the 
NEOPAIN trial. Pediatrics 2005;115(5):1351-1359. 
Hammarberg B. Voice research and clinical needs. Folia Phoniatr Logop 2000;52(1-3):93-102. 
Hammarberg B, Gauffin J. Perceptual and Acoustic Characteristics of Quality Difference in 
Pathological Voices as Related to Physiological Aspects. In: FH Osamu, editor Book 
Title|, Vol. Volume|. City|: Publisher|, Year|. p.^pp. Pages|. 
Harrop JE. Management of pain in childhood. Arch Dis Child Educ Pract Ed 2007;92(4):ep101-
108. 
 
 
 
71 
 
Hartley R, Green M, Quinn M, Levene MI. Pharmacokinetics of morphine infusion in premature 
neonates. Arch Dis Child 1993;69(1 Spec No):55-58. 
Högberg U, Hakansson S, Serenius F, Holmgren PA. Extremely preterm cesarean delivery: a 
clinical study. Acta Obstet Gynecol Scand 2006;85(12):1442-1447. 
Hosti L, Grunau RE, Oblander TF, Osiovich H. Is it painful or not? Discriminant validity of the 
Behavioral Indicators of Infant Pain (BIPP) scale. Clin J Pain 2008;24(1):83-8. 
IASP.  
International Association for the Study of Pain SoT. Pain terms: a list with definitions and notes 
on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 1979;6(3):249-
252. 
Jackman A, Fitzgerald M. Development of peripheral hindlimb and central spinal cord 
innervation by subpopulations of dorsal root ganglion cells in the embryonic rat. J Comp 
Neurol 2000;418(3):281-298. 
Jacqz-Aigrain E, Burtin P. Clinical pharmacokinetics of sedatives in neonates. Clin 
Pharmacokinet 1996;31(6):423-443. 
Johnston CC, Stevens B, Craig KD, Grunau RV. Developmental changes in pain expression in 
premature, full-term, two- and four-month-old infants. Pain 1993;52(2):201-208. 
Johnston CC, Stevens B, Yang F, Horton L. Developmental changes in response to heelstick in 
preterm infants: a prospective cohort study. Developmental Medicine & Child 
Neurology 1996;38(5):438-445. 
Johnston CC, Stevens BJ. Experience in a neonatal intensive care unit affects pain response. 
Pediatrics 1996;98(5):925-930. 
Johnston CC, Strada ME. Acute pain response in infants: a multidimensional description. Pain 
1986;24(3):373-382. 
Kamibayashi T, Maze M. Clinical uses of alpha2 -adrenergic agonists. Anesthesiology 
2000;93(5):1345-1349. 
Kar S, Quirion R. Neuropeptide receptors in developing and adult rat spinal cord: an in vitro 
quantitative autoradiography study of calcitonin gene-related peptide, neurokinins, mu-
opioid, galanin, somatostatin, neurotensin and vasoactive intestinal polypeptide 
receptors. J Comp Neurol 1995;354(2):253-281. 
Kauffman RE. Guidelines for the Ethical Conduct of Studies to evaluate Drugs in Pediatric 
Populations. Pediatrics 1995;95(2):286-294. 
Kauffman RE. Clinical trials in children: problems and pitfalls. Paediatr Drugs 2000;2(6):411-
418. 
Krechel SW, Bildner J. CRIES: a new neonatal postoperative pain measurement score. Initial 
testing of validity and reliability. Paediatr Anaesth 1995;5(1):53-61. 
Lagercrantz H. Stress, Arousal, and Gene Activation at Birth. News Physiol Sci 1996;11:214-
218. 
Lagercrantz H, Hansson M, Evrard P, Rodeck C, The Newborn Brain: Neuroscience and 
Clinical Applications, Vol. 1. Cambridge: Cambridge University Press, 2002. 
Lagercrantz H, Slotkin TA. The "stress" of being born. Sci Am 1986;254(4):100-107. 
Larsson BA, Tannfeldt G, Lagercrantz H, Olsson GL. Venipuncture is more effective and less 
painful than heel lancing for blood tests in neonates. Pediatrics 1998;101(5):882-886. 
Lawrence J, Alcock D, McGrath P, Kay J, MacMurray SB, Dulberg C. The development of a 
tool to assess neonatal pain. Neonatal Netw 1993;12(6):59-66. 
Lester BM. A biosocial model of infant crying. New York: Academic, 1984. 
Levene M. Fetal and Neonatal Neurology and Neurosurgery. Livingstone, Edinburgh: Elsevier 
Science Limited, 2001. 
Levene M. Morphine sedation in ventilated newborns: who are we treating? Pediatrics 
2005;116(2):492-493. 
Levene MI, Quinn MW. Use of sedatives and muscle relaxants in newborn babies receiving 
mechanical ventilation. Arch Dis Child 1992;67(7 Spec No):870-873. 
Lindam A. Graviditet, Förlossningar och Nyfödda Barn, Socialstyrelsens Birth register 1973-
2006. In: SHo sjukdommar, editor Book Title|, Vol. Volume|. City|: Publisher|, Year|. 
p.^pp. Pages|. 
 
 72 
 
Lindh V, Wiklund U, Sandman PO, Hakansson S. Assessment of acute pain in preterm infants 
by evaluation of facial expression and frequency domain analysis of heart rate 
variability. Early Hum Dev 1997;48(1-2):131-142. 
Marsh DF, Hatch DJ, Fitzgerald M. Opioid systems and the newborn. Br J Anaesth 
1997;79(6):787-795. 
Masciello AL. Anesthesia for neonatal circumcision: local anesthesia is better than dorsal penile 
nerve block. Obstet Gynecol 1990;75(5):834-838. 
Maxwell LG, Yaster M, Wetzel RC, Niebyl JR. Penile nerve block for newborn circumcision. 
Obstet Gynecol 1987;70(3 Pt 1):415-419. 
McIntosh N, Van Veen L, Brameyer H. The pain of heel prick and its measurement in preterm 
infants. Pain 1993;52(1):71-74. 
McIntosh N, van Veen L, Brameyer H. Alleviation of the pain of heel prick in preterm infants. 
Arch Dis Child Fetal Neonatal Ed 1994;70(3):F177-181. 
Merskey H. The definition of Pain. Eur J Psychiatry 1991;6:153-159. 
Michelsson K, Jarvenpaa AL, Rinne A. Sound spectrographic analysis of pain cry in preterm 
infants. Early Hum Dev 1983;8(2):141-149. 
Michelsson K, Michelsson O. Phonation in the newborn, infant cry. Int J Pediatr 
Otorhinolaryngol 1999;49 Suppl 1:S297-301. 
Mogil JS, Sternberg WF, Balian H, Liebeskind JC, Sadowski B. Opioid and nonopioid swim 
stress-induced analgesia: a parametric analysis in mice. Physiol Behav 1996;59(1):123-
132. 
Nagy Z, Westerberg H, Skare S, Andersson JL, Lilja A, Flodmark O, Fernell E, Holmberg K, 
Bohm B, Forssberg H, Lagercrantz H, Klingberg T. Preterm children have disturbances 
of white matter at 11 years of age as shown by diffusion tensor imaging. Pediatr Res 
2003;54(5):672-679. 
Nandi R, Beacham D, Middleton J, Koltzenburg M, Howard RF, Fitzgerald M. The functional 
expression of mu opioid receptors on sensory neurons is developmentally regulated; 
morphine analgesia is less selective in the neonate. Pain 2004;111(1-2):38-50. 
Narsinghani U, Anand KJ. Developmental Neurobiology of Pain in Neonatal Rats. Lab Anim 
(NY) 2000;29(9):27-39. 
Nozaki-Taguchi N, Yaksh TL. Characterization of the antihyperalgesic action of a novel 
peripheral mu-opioid receptor agonist--loperamide. Anesthesiology 1999;90(1):225-234. 
Olsson GL, Meyerson BA, Linderoth B. Spinal cord stimulation in adolescents with complex 
regional pain syndrome type I (CRPS-I). Eur J Pain. 2008 Jan;12(1):53-9. Epub 2007 Sep 21. 
Payne J, Middleton J, Fitzgerald M. The pattern and timing of cutaneous hair follicle innervation 
in the rat pup and human fetus. Brain Res Dev Brain Res 1991;61(2):173-182. 
Pernick SM. A Calculus of Suffering: Pain, Professionalism, and Anesthesia in Nineteenth-
Century America. New York: Columbia University Press, 1985. 
Porter FL, Grunau RE, Anand KJ. Long-term effects of pain in infants. J Dev Behav Pediatr 
1999;20(4):253-261. 
Porter FL, Miller RH, Marshall RE. Neonatal pain cries: effect of circumcision on acoustic 
features and perceived urgency. Child Dev 1986;57(3):790-802. 
Porter FL, Porges SW, Marshall RE. Newborn pain cries and vagal tone: parallel changes in 
response to circumcision. Child Dev 1988;59(2):495-505. 
Quinn MW, Otoo F, Rushforth JA, Dean HG, Puntis JW, Wild J, Levene MI. Effect of 
morphine and pancuronium on the stress response in ventilated preterm infants. Early 
Hum Dev 1992;30(3):241-248. 
Rahman W, Dashwood MR, Fitzgerald M, Aynsley-Green A, Dickenson AH. Postnatal 
development of multiple opioid receptors in the spinal cord and development of spinal 
morphine analgesia. Brain Res Dev Brain Res 1998;108(1-2):239-254. 
Raisanen I, Paatero H, Salminen K, Laatikainen T. Beta-endorphin in maternal and umbilical 
cord plasma at elective cesarean section and in spontaneous labor. Obstet Gynecol 
1986;67(3):384-387. 
Reynolds ML, Fitzgerald M. Long-term sensory hyperinnervation following neonatal skin 
wounds. J Comp Neurol 1995;358(4):487-498. 
Reynolds ML, Fitzgerald M, Benowitz LI. GAP-43 expression in developing cutaneous and 
muscle nerves in the rat hindlimb. Neuroscience 1991;41(1):201-211. 
Ruda MA, Ling QD, Hohmann AG, Peng YB, Tachibana T. Altered nociceptive neuronal 
circuits after neonatal peripheral inflammation. Science 2000;289(5479):628-631. 
 
 
 
73 
 
Runefors P, Arnbjonsson E. A sound spectrogram analysis of children's crying after painful 
stimuli during the first year of life. Folia Phoniatr Logop 2005;57(2):90-95. 
Runefors P, Arnbjornsson E, Elander G, Michelsson K. Newborn infants' cry after heel-prick: 
analysis with sound spectrogram. Acta Paediatr 2000;89(1):68-72. 
Rushforth JA, Levene MI. Behavioural response to pain in healthy neonates. Arch Dis Child 
Fetal Neonatal Ed 1994;70(3):F174-176. 
Saarenmaa E, Neuvonen PJ, Fellman V. Gestational age and birth weight effects on plasma 
clearance of fentanyl in newborn infants. J Pediatr 2000a;136(6):767-770. 
Saarenmaa E, Neuvonen PJ, Rosenberg P, Fellman V. Morphine clearance and effects in 
newborn infants in relation to gestational age. Clin Pharmacol Ther 2000b;68(2):160-
166. 
Scott CS, Riggs KW, Ling EW, Fitzgerald CE, Hill ML, Grunau RV, Solimano A, Craig KD. 
Morphine pharmacokinetics and pain assessment in premature newborns. J Pediatr 
1999;135(4):423-429. 
Serenius F, Ewald U, Farooqi A, Holmgren PA, Hakansson S, Sedin G. Short-term outcome 
after active perinatal management at 23-25 weeks of gestation. A study from two 
Swedish perinatal centres. Part 3: neonatal morbidity. Acta Paediatr 2004;93(8):1090-
1097. 
Shah AR, Kurth CD, Gwiazdowski SG, Chance B, Delivoria-Papadopoulos M. Fluctuations in 
cerebral oxygenation and blood volume during endotracheal suctioning in premature 
infants. J Pediatr 1992;120(5):769-774. 
Shah PS, Aliwalas LI, Shah V. Breastfeeding or breast milk for procedural pain in neonates. 
Cochrane Database Syst Rev 2006;3:CD004950. 
Simons SH, Anand KJ. Pain control: opioid dosing, population kinetics and side-effects. Semin 
Fetal Neonatal Med 2006;11(4):260-267. 
Simons SH, Tibboel D. Pain perception development and maturation. Semin Fetal Neonatal 
Med 2006;11(4):227-231. 
Simons SH, van Dijk M, Anand KS, Roofthooft D, van Lingen RA, Tibboel D. Do we still hurt 
newborn babies? A prospective study of procedural pain and analgesia in neonates. Arch 
Pediatr Adolesc Med 2003;157(11):1058-1064. 
Skov L, Ryding J, Pryds O, Greisen G. Changes in cerebral oxygenation and cerebral blood 
volume during endotracheal suctioning in ventilated neonates. Acta Paediatr 
1992;81(5):389-393. 
Slater R, Cantarella A, Franck L, Meek J, Fitzgerald M. How well do clinical pain assessment 
tools reflect pain in infants? PLoS Med 2008;5(6):e129. 
Snider WD. Functions of the neurotrophins during nervous system development: what the 
knockouts are teaching us. Cell 1994;77(5):627-638. 
Sowell ER, Trauner DA, Gamst A, Jernigan TL. Development of cortical and subcortical brain 
structures in childhood and adolescence: a structural MRI study. Dev Med Child Neurol 
2002;44(1):4-16. 
Sparshott M. Assessing the behaviour of the newborn infant. Paediatr Nurs 1995;7(7):14-16, 36. 
Spencer W. Celsus on Medicine. Harvard University Press 1994;3:391-421. 
Stenqvist O. Inhalationsanestesi. In: MAB Halldin, SGE Lindahl, editors|. Book Title|, Vol. 
Volume|. City|: Publisher|, Year|. p.^pp. Pages|. 
Stevens B, Franck L, Gibbins S, McGrath PJ, Dupuis A, Yamada J, Beyene J, Camfield C, 
Finley GA, Johnston C, O'Brien K, Ohlsson A. Determining the structure of acute pain 
responses in vulnerable neonates. Can J Nurs Res 2007;39(2):32-47. 
Stevens B, Johnston C, Franck L, Petryshen P, Jack A, Foster G. The efficacy of 
developmentally sensitive interventions and sucrose for relieving procedural pain in very 
low birth weight neonates. Nurs Res 1999;48(1):35-43. 
Stevens B, Johnston C, Gibbins S. Pain assessment in neonates. In: KJS Anand, BJ Stevens, PJ 
McGrath, editors|. Book Title|, Vol. Volume|. City|: Publisher|, Year|. p.^pp. Pages|. 
Stevens B, Johnston C, Petryshen P, Taddio A. Premature Infant Pain Profile: development and 
initial validation. Clin J Pain 1996;12(1):13-22. 
Stevens B, Yamada J, Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful 
procedures. Cochrane Database Syst Rev 2004(3):CD001069. 
 74 
 
Stevens BJ, Franck LS. Assessment and management of pain in neonates. Paediatr Drugs 
2001;3(7):539-558. 
Stevens BJ, Johnston CC. Physiological responses of premature infants to a painful stimulus. 
Nurs Res 1994;43(4):226-231. 
Stevens BJ, Johnston CC, Horton L. Factors that influence the behavioral pain responses of 
premature infants. Pain 1994;59(1):101-109. 
Still GF. The history of Paediatrics: The progress of the study of diseases of children up to the 
end of the XVIIIth century. London: Oxford University Press, 1931. 
Stiller CO, Gustafsson H, Fried K, Brodin E. Opioid-induced release of neurotensin in the 
periaqueductal gray matter of freely moving rats. Brain Res 1997;774(1-2):149-158. 
Suri A, Estes KS, Geisslinger G, Derendorf H. Pharmacokinetic-pharmacodynamic relationships 
for analgesics. Int J Clin Pharmacol Ther 1997;35(8):307-323. 
Swafford L, Allen, D. Relief in pediatric patients. Med Clin North Am 1968;52:131-136. 
Taddio A, Goldbach M, Ipp M, Stevens B, Koren G. Effect of neonatal circumcision on pain 
responses during vaccination in boys. Lancet 1995;345(8945):291-292. 
Taddio A, Katz J, Ilersich AL, Koren G. Effect of neonatal circumcision on pain response during 
subsequent routine vaccination. Lancet 1997;349(9052):599-603. 
Taylor BJ, Robbins JM, Gold JI, Logsdon TR, Bird TM, Anand KJ. Assessing postoperative 
pain in neonates: a multicenter observational study. Pediatrics 2006;118(4):e992-1000. 
Teixeira JM, Glover V, Fisk NM. Acute cerebral redistribution in response to invasive 
procedures in the human fetus. Am J Obstet Gynecol 1999;181(4):1018-1025. 
Volpe JJ. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res 
2001;50(5):553-562. 
Westrup B, Bohm B, Lagercrantz H, Stjernqvist K. Preschool outcome in children born very 
prematurely and cared for according to the Newborn Individualized Developmental Care 
and Assessment Program (NIDCAP). Acta Paediatr 2004;93(4):498-507. 
Wyatt JS, Cope M, Delpy DT, Richardson CE, Edwards AD, Wray S, Reynolds EO. 
Quantitation of cerebral blood volume in human infants by near-infrared spectroscopy. J 
Appl Physiol 1990;68(3):1086-1091. 
Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol 
Scand 1997;41(1 Pt 2):94-111. 
 
 
